JNJ


Line plots across dimensions of each concept
Line plots across concepts
Tables

Table of contents



us-gaap:CommonStockSharesIssued

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

us-gaap:EarningsPerShareBasic

us-gaap:EarningsPerShareDiluted

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:CostOfGoodsAndServicesSold

us-gaap:GrossProfit

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

us-gaap:IncomeTaxExpenseBenefit

us-gaap:InterestExpense
us-gaap:StatementBusinessSegments
us-gaap:LitigationSettlementExpense

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents
us-gaap:ConsolidationItems
us-gaap:OperatingIncomeLoss
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

us-gaap:OtherComprehensiveIncomeLossNetOfTax
us-gaap:StatementEquityComponents

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementBusinessSegments
us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments, us-gaap:Subsegments
us-gaap:StatementBusinessSegments
us-gaap:StatementBusinessSegments, us-gaap:Subsegments
us-gaap:StatementGeographical
us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments
us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments, us-gaap:Subsegments

us-gaap:Revenues

us-gaap:SellingGeneralAndAdministrativeExpense

us-gaap:Assets
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:StatementBusinessSegments

us-gaap:Liabilities

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:AssetsCurrent

us-gaap:CashAndCashEquivalentsAtCarryingValue
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:MarketableSecuritiesCurrent
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AccountsReceivableNetCurrent

us-gaap:InventoryNet

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:Land

us-gaap:MachineryAndEquipmentGross
us-gaap:ConsolidationItems
us-gaap:NoncurrentAssets
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:ConsolidationItems, us-gaap:StatementGeographical
us-gaap:PropertyPlantAndEquipmentByType

us-gaap:PropertyPlantAndEquipmentGross

us-gaap:ConstructionInProgressGross

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

us-gaap:AmortizationOfIntangibleAssets

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:Goodwill
us-gaap:BusinessAcquisition
us-gaap:StatementBusinessSegments

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

us-gaap:IntangibleAssetsNetExcludingGoodwill
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FiniteLivedIntangibleAssetsNet
us-gaap:BusinessAcquisition, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:IntangibleAssetsNetIncludingGoodwill

us-gaap:DeferredTaxAssetsLiabilitiesNet

us-gaap:OtherAssetsNoncurrent
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

us-gaap:EquitySecuritiesFvNi
us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:AccountsPayableCurrent

us-gaap:AccruedIncomeTaxesCurrent

us-gaap:AccruedLiabilitiesCurrent

us-gaap:DebtCurrent

us-gaap:LiabilitiesCurrent
us-gaap:FairValueByMeasurementBasis
us-gaap:LongTermDebtCurrent
us-gaap:BusinessAcquisition, us-gaap:LongtermDebtType
us-gaap:LongTermDebt
us-gaap:DebtInstrument
us-gaap:FairValueByMeasurementBasis
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:LineOfCreditFacility, us-gaap:LongtermDebtType

us-gaap:LongTermDebtNoncurrent

us-gaap:DeferredIncomeTaxLiabilitiesNet

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
us-gaap:RetirementPlanType

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OperatingLeaseLiability

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:TreasuryStockValue

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:DeferredIncomeTaxExpenseBenefit

us-gaap:DepreciationDepletionAndAmortization

us-gaap:IncreaseDecreaseInAccountsReceivable

us-gaap:IncreaseDecreaseInInventories

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents

us-gaap:ShareBasedCompensation

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:PaymentsToAcquireInvestments

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:ProceedsFromIssuanceOfLongTermDebt

us-gaap:RepaymentsOfLongTermDebt

us-gaap:PaymentsForRepurchaseOfCommonStock

us-gaap:EffectiveIncomeTaxRateContinuingOperations

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:DeferredTaxLiabilities

us-gaap:DeferredTaxAssetsNet

us-gaap:UnrecognizedTaxBenefits
us-gaap:BalanceSheetLocation

jnj:AmountPrepaidAndDueToManufacturers

jnj:CostOfGoodsSoldPercentToSales

jnj:EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent

jnj:EffectiveIncomeTaxReconciliationPercentRevisedAgreementFromLitigationSettlement

jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable
jnj:EquityFairValueAdjustmentImpairmentLoss
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable
jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
jnj:EquityMethodInvestmentRetainedAfterDisposalOwnershipInterestAfterDisposalShares

jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue

jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset

jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent

jnj:GrossProfitPercentToSales

jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales

jnj:IncomeTaxExpenseBenefitPercentToSales

jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI

jnj:InterestExpensePercentToSales

jnj:InvestmentIncomeInterestPercentToSales
us-gaap:ProductOrService, us-gaap:LitigationStatus
jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue

jnj:NetIncomeAttributableToParentPercentToSales

jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax

jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax

jnj:OtherNonOperatingIncomeExpensePercentToSales

jnj:PercentageChangeInOperatingIncomeLoss
us-gaap:ConsolidationItems
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

jnj:PercentageChangeInSalesByGeographicArea
us-gaap:StatementGeographical

jnj:PercentageChangeInSalesBySegmentOfBusiness

jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits

jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities

jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities

jnj:Proceedsfromcreditsupportagreements

jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales

jnj:ResearchAndDevelopmentInProcessPercentToSales

jnj:Restructuringchargepercenttosales

jnj:SalesRevenueGoodsNetPercentToSales

jnj:SellingGeneralAndAdministrativeExpensePercentToSales

jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:AdjustmentForAmortization

us-gaap:AssetImpairmentCharges
us-gaap:BusinessAcquisition, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:BusinessAcquisition
us-gaap:BusinessCombinationConsiderationTransferred1
us-gaap:BusinessAcquisition, us-gaap:SubsequentEventType

us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
us-gaap:BusinessAcquisition
us-gaap:BusinessAcquisition, us-gaap:IncomeStatementLocation, us-gaap:StatementBusinessSegments

us-gaap:CommonStockDividendsPerShareCashPaid

us-gaap:CommonStockDividendsPerShareDeclared
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanInterestCost
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanServiceCost
us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:IncomeStatementLocation
us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation, us-gaap:IncomeStatementLocation
us-gaap:DerivativeGainLossOnDerivativeNet
us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:IncomeStatementLocation
us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred

us-gaap:DividendsCommonStockCash
us-gaap:StatementEquityComponents

us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable
us-gaap:EquityFairValueAdjustment

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:GainLossOnDispositionOfAssets1
us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations

us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges

us-gaap:GoodwillOtherIncreaseDecrease
us-gaap:StatementBusinessSegments
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

us-gaap:IncreaseDecreaseInOtherOperatingAssets

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities

us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

us-gaap:InvestmentIncomeInterest
us-gaap:LitigationCase, us-gaap:LitigationStatus
us-gaap:LossContingencyDamagesAwardedValue
us-gaap:ProductOrService, us-gaap:LitigationStatus
us-gaap:LitigationCase, us-gaap:LitigationStatus, us-gaap:LossContingenciesByNatureOfContingency
us-gaap:LossContingencyDamagesSoughtValue

us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1

us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1

us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax

us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
us-gaap:DerivativeInstrumentRisk, us-gaap:DerivativeInstrumentsGainLossByHedgingRelationship, us-gaap:IncomeStatementLocation
us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax

us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
us-gaap:DerivativeInstrumentRisk

us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
us-gaap:LitigationCase, us-gaap:LitigationStatus, us-gaap:LossContingenciesByNatureOfContingency
us-gaap:PaymentsForLegalSettlements

us-gaap:PaymentsForProceedsFromOtherInvestingActivities
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
us-gaap:PaymentsForRestructuring
us-gaap:RestructuringPlan

us-gaap:PaymentsOfOrdinaryDividends

us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
us-gaap:RetirementPlanSponsorLocation
us-gaap:PensionContributions
us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations, us-gaap:SubsequentEventType
us-gaap:ProceedsFromDivestitureOfBusinesses

us-gaap:ProceedsFromPaymentsForOtherFinancingActivities

us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments

us-gaap:ProceedsFromSaleOfProductiveAssets

us-gaap:ProceedsFromShortTermDebt

us-gaap:ProvisionForDoubtfulAccounts

us-gaap:RepaymentsOfShortTermDebt

us-gaap:ResearchAndDevelopmentInProcess
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:RestructuringCharges
us-gaap:IncomeStatementLocation, us-gaap:RestructuringPlan
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
us-gaap:RestructuringPlan
us-gaap:StatementBusinessSegments
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
us-gaap:RestructuringReserveSettledWithoutCash2
us-gaap:RestructuringPlan
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:SaleOfStockConsiderationReceivedPerTransaction
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:SubsequentEventType
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction

us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
us-gaap:StatementEquityComponents

us-gaap:StockholdersEquityOther
us-gaap:StatementEquityComponents

us-gaap:TreasuryStockValueAcquiredCostMethod
us-gaap:StatementEquityComponents
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:UnrealizedGainLossOnSecurities

dei:EntityCommonStockSharesOutstanding

jnj:AccruedProfessionalFeesRevisedAgreementFromLitigationSettlement

jnj:AccruedRebatesReturnsAndPromotions
us-gaap:StatementBusinessSegments
us-gaap:BusinessAcquisition
jnj:BusinessAcquisitionDiscountRate
us-gaap:Range, us-gaap:BusinessAcquisition
jnj:BusinessCombinationProbabilityOfSuccessFactor

jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue

jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized

jnj:DeferredTaxAssetsOtherDomestic

jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization

jnj:DeferredTaxAssetsUndistributedForeignEarnings

jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome
us-gaap:DefinedBenefitPlanByPlanAssetCategories, us-gaap:FairValueByMeasurementFrequency, us-gaap:RetirementPlanType
jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
us-gaap:FairValueByMeasurementFrequency, us-gaap:RetirementPlanType

jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter

jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive

jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour

jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne

jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree

jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo
us-gaap:PlanName, us-gaap:RetirementPlanSponsorLocation
jnj:DefinedBenefitPlanOverUnderFundedStatusABO

jnj:EmployeeObligations

jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets
us-gaap:LitigationStatus
jnj:LossContingencyEstimateOfAdditionalPossibleLoss
us-gaap:LitigationStatus, us-gaap:SubsequentEventType

jnj:NumberOfStockBasedCompensationPlans
us-gaap:LitigationCase, us-gaap:LitigationStatus
jnj:Numberofpatientsinsettlement
us-gaap:ConsolidationItems
jnj:OtherNonLongLivedAssets

jnj:PercentageOfCompanysCommonStockToPlanAsset

jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets
us-gaap:ProductOrService
jnj:ProductLiabilityContingencyNumberOfClaimant
us-gaap:ProductOrService, us-gaap:LitigationStatus

jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability

jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent

us-gaap:AccruedIncomeTaxesNoncurrent

us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent

us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax

us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableForSaleSecuritiesCurrent

us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate

us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis

us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:BuildingsAndImprovementsGross

us-gaap:BusinessCombinationContingentConsiderationLiability
us-gaap:BalanceSheetLocation
us-gaap:BalanceSheetLocation, us-gaap:BusinessAcquisition
us-gaap:BusinessAcquisition
us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:BusinessAcquisition
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets

us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
us-gaap:BusinessAcquisition
us-gaap:BusinessAcquisition
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
us-gaap:BusinessAcquisition, us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:CashCashEquivalentsAndShortTermInvestments
us-gaap:DerivativeInstrumentRisk
us-gaap:CollateralAlreadyPostedAggregateFairValue

us-gaap:DebtInstrumentInterestRateEffectivePercentage
us-gaap:ShortTermDebtType
us-gaap:DebtWeightedAverageInterestRate

us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent

us-gaap:DeferredIncomeTaxAssetsNet

us-gaap:DeferredTaxAssetsDeferredIncome

us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign

us-gaap:DeferredTaxAssetsOther

us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals

us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

us-gaap:DeferredTaxLiabilitiesOther

us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings

us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
us-gaap:PlanName, us-gaap:RetirementPlanSponsorLocation
us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet

us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
us-gaap:PlanName, us-gaap:RetirementPlanSponsorLocation
us-gaap:DefinedBenefitPlanBenefitObligation
us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
us-gaap:PlanName, us-gaap:RetirementPlanSponsorLocation
us-gaap:DefinedBenefitPlanFundedStatusOfPlan
us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear

us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation

us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets

us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation

us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
us-gaap:DefinedBenefitPlanByPlanAssetCategories

us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1

us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
us-gaap:DefinedBenefitPlanByPlanAssetCategories

us-gaap:DerivativeAssetFairValueGrossLiability

us-gaap:DerivativeAssets

us-gaap:DerivativeFairValueOfDerivativeAsset

us-gaap:DerivativeFairValueOfDerivativeLiability
us-gaap:BalanceSheetLocation, us-gaap:HedgingDesignation

us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
us-gaap:DerivativeInstrumentRisk
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
us-gaap:DerivativeInstrumentRisk
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:DerivativeLiabilities

us-gaap:DerivativeLiabilityFairValueGrossAsset
us-gaap:DerivativeInstrumentRisk
us-gaap:DerivativeNotionalAmount
us-gaap:DisposalGroupClassification, us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations
us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent

us-gaap:EmployeeRelatedLiabilitiesCurrent

us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
us-gaap:BusinessAcquisition
us-gaap:EquityMethodInvestmentsFairValueDisclosure
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FiniteLivedIntangibleAssetsGross
us-gaap:DerivativeInstrumentRisk
us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:DerivativeInstrumentRisk
us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:BalanceSheetLocation, us-gaap:HedgingDesignation
us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:HeldToMaturitySecurities
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:HeldToMaturitySecuritiesFairValue
us-gaap:InformationByCategoryOfDebtSecurity
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:InventoryFinishedGoodsNetOfReserves

us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves

us-gaap:InventoryWorkInProcessNetOfReserves
dei:LegalEntity, us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:CreditFacility, us-gaap:LongtermDebtType
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
us-gaap:BusinessAcquisition
us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity

us-gaap:LongTermCommercialPaperCurrent

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

us-gaap:LongtermDebtWeightedAverageInterestRate
us-gaap:LitigationStatus
us-gaap:LossContingencyEstimateOfPossibleLoss
us-gaap:LitigationStatus, us-gaap:SubsequentEventType
us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable
us-gaap:MarketableSecuritiesNoncurrent

us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
us-gaap:RetirementPlanType

us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent
us-gaap:RestructuringPlan
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
us-gaap:RestructuringCostAndReserve, us-gaap:RestructuringPlan
us-gaap:RestructuringReserve
us-gaap:RestructuringCostAndReserve, us-gaap:StatementBusinessSegments
us-gaap:RestructuringPlan
us-gaap:StatementBusinessSegments
us-gaap:BusinessAcquisition
us-gaap:SaleOfStockPricePerShare
us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
us-gaap:ShareRepurchaseProgram
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
us-gaap:ShareRepurchaseProgram
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRange

us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRange

us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRange

us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRange

us-gaap:ShortTermBorrowings
us-gaap:FairValueByMeasurementBasis
us-gaap:ShortTermDebtType

us-gaap:StockholdersEquityBeforeTreasuryStock

us-gaap:TreasuryStockShares

us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued

Plots across concepts


IncomeStatement
Other Comprehensive Income Loss Net Of Tax
Expenses
Interest Expense
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Derivative Assets
Current Assets
Prepaid Expense And Other Assets Current
NonCurrent Assets
Operating Lease Right Of Use Asset
PropertyPlantAndEquipmentNet
Property Plant And Equipment Net
Liabilities
Derivative Liabilities
Current Liabilities
Accrued Income Taxes Current
Noncurrent Liabilities
Accrued Income Taxes Noncurrent
Stockholders Equity
Accumulated Other Comprehensive Income Loss Net Of Tax
Per Share
Common Stock Dividends Per Share Declared
CashFlow
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInOperatingActivities
Increase Decrease In Accounts Receivable
NetCashProvidedByUsedInInvestingActivities
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInFinancingActivities
Net Cash Provided By Used In Financing Activities
Shares
Treasury Stock Shares
DividendsAndRepurchase
Payments For Repurchase Of Common Stock
InventoryNet
Inventory Work In Process Net Of Reserves
AccountsReceivable
Allowance For Doubtful Accounts Receivable Current

Tables

  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:CommonStockSharesIssued ▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁█▁▁▁▁▁3119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433119.8433120.03119.8433119.8433119.8433119.8433119.843NANANA3119.843NANANA
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding ▇█▅▁▆2671.62672.72669.32665.52671.0NA2669.92691.72698.8NA2727.62721.32731.9NA2737.72741.52754.5NA2785.42794.22795.4NA2807.22812.02826.0NA2864.32874.22874.7NA2881.22893.02858.8NA2818.12798.22774.9NA2778.22781.32772.7NA2786.42796.02797.3NANANANA
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic ▄▁▄▅█2632.52631.62632.52632.92633.7NA2635.22652.52660.8NA2683.22682.32682.2NA2684.62691.92706.6NA2731.62745.42757.2NA2768.42772.32782.6NA2814.42826.42826.8NA2818.42809.72790.2NA2757.42747.42736.9NA2737.02740.52738.4NA2751.62756.62755.4NANANANA
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount NA9.020.020.010.0NA19.0NA0.0NA0.017.00.0NA0.00.00.0NA0.00.00.0NA20.0NANANANANANANANANANANANA57.050.0NA51.051.093.0NA86.068.055.0NANANANA
us-gaap:EarningsPerShareBasic ██▇▇█▇▆█▇▇▇▇▇▁▇▇▇▇▇▇▇▇▇▇▇▆▇▇▇▇▇▇▇▆▇▆▇▅▇▆▇▆▇▇▇▆▇▇▇2.382.351.351.382.21.520.672.111.411.141.471.471.63-3.991.41.421.631.411.561.461.561.161.211.631.550.91.691.531.671.251.061.361.250.931.080.511.430.081.171.011.270.711.241.251.640.81.211.161.27
us-gaap:EarningsPerShareDiluted ██▇▇█▇▆█▇▇▇▇▇▁▇▇▇▇▇▇▇▇▇▇▇▆▇▇▇▇▇▇▇▆▇▆▇▅▇▇▇▆▇▇▇▆▇▇▇2.352.321.331.362.171.50.662.081.391.121.441.451.6-3.991.371.41.611.381.531.431.541.151.21.611.530.891.661.511.641.231.041.331.220.911.050.51.410.081.151.01.250.71.231.231.620.791.21.151.26
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:ComprehensiveIncomeNetOfTax █▇▁▂▅6506.06111.04149.04336.05444.0NA1189.06155.03454.0NA4064.01785.05190.0NA4251.05115.04801.0NA4264.03681.05066.0NA2551.05762.01742.0-2819.02374.03964.04942.06005.04446.03712.02618.01682.04247.0-256.05002.0-2346.01324.0NANANANANANANANANANA
us-gaap:CostOfGoodsAndServicesSold █▄▄▁▄▅▃▄▁▄▁▃▁▆▃7587.07063.06972.06579.07062.07134.06867.06940.06615.06961.06589.06927.06614.07259.06925.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:GrossProfit █▇▆▃▅▅▆▅▅▅▅▆▅▄▄▄▄▄▄▅▃▃▃▄▃▄▅▅▄▄▃▄▃▃▂▂▂▂▂▂▂▁▁▁▂▂▁▂▂15725.015258.014110.011757.013629.013613.013862.013622.013406.013433.013759.013903.013395.012952.012748.013016.012380.012572.012334.013146.012153.012138.011878.012430.012092.012401.013068.013456.012660.012400.012231.012388.011951.011555.011455.011332.011224.010917.010933.011425.011395.010604.010388.010700.011103.011239.010647.010789.010775.0
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments ▇█▅▅▇▅▂█▅▄▅▆▆▃▅▅▆▅▆▆▆▄▅▆▆▃▇▆▆▃▄▅▅▄▄▃▆▁▅▄▅▃▅▅▇▃▅▅▅6662.07429.04401.03940.06509.04218.01647.07041.04422.03122.04423.04973.05481.02560.04790.04748.05575.04324.05281.04904.05294.03758.04122.05741.05575.02703.06810.05626.05424.02750.03667.04793.04261.03100.03595.02035.05045.0318.04111.03422.04510.02228.04219.04220.06280.02604.04245.04263.04643.0
us-gaap:IncomeTaxExpenseBenefit ▁▂▁▁▁▁▁▂▁▁▁▂▂█▂▂▂▁▂▂▂384.01232.0847.0314.0713.0208.0-106.01434.0673.080.0489.01019.01114.013273.01026.0921.01153.0510.01009.0907.01002.0NA764.01225.01255.0182.02061.01300.0697.0-769.0685.0960.0764.0533.0966.0627.01135.0100.0909.0646.01034.0286.0802.0771.01754.0NANANANA
us-gaap:InterestExpense ▁▂▂▂▁▃▂▃▃▇▇▇██▇▇▆▅▆▆▅40.063.044.045.025.085.048.083.0102.0250.0243.0253.0259.0274.0229.0227.0204.0184.0192.0190.0160.0NA123.0131.0138.0139.0130.0128.0136.0134.0105.0118.0125.0107.0135.0143.0147.0183.0134.0129.0125.0138.0108.0101.0108.0NANANANA
 us-gaap:LitigationSettlementExpense us-gaap:StatementBusinessSegments jnj:Consumer100.0NA500.0600.0NA200.00.0200.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LitigationSettlementExpense us-gaap:StatementBusinessSegments jnj:PharmaceuticalNANA1000.0NA100.00.04000.0100.0300.0NANANANA17.0NANANANANANA136.0NA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:NetIncomeLoss ██▇▇█▇▆█▇▇▇▇▇▁▇▇▇▇▇▇▇▇▇▇▇▆▇▇▇▇▇▇▇▆▇▆▇▆▇▇▇▆▇▇▇▆▇▇▇6278.06197.03554.03626.05796.04010.01753.05607.03749.03042.03934.03954.04367.0-10713.03764.03827.04422.03814.04272.03997.04292.03215.03358.04516.04320.02521.04749.04326.04727.03519.02982.03833.03497.02567.02968.01408.03910.0218.03202.02776.03476.01942.03417.03449.04526.02206.03345.03208.03507.0
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems us-gaap:CorporateNonSegment█▆▇█▁244.0211.0239.0252.0120.0NA176.0231.0147.0NA230.0303.0312.0NA328.0316.0247.0NA233.0293.0192.0NA256.0282.0252.0NA243.0249.0NANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems us-gaap:OperatingSegments▇█▂▁▆6906.07640.04640.04192.06629.0NA1823.07272.04569.0NA4653.05276.05793.0NA5118.05064.05822.0NA5514.05197.05486.0NA4378.06023.05827.0NA7053.05875.0NANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,jnj:Consumer██▂▁█804.0788.0191.032.0770.0NA653.0406.0741.0NA510.0829.0548.0NA878.0658.0596.0NA679.0571.0566.0NA811.0317.0644.0NA407.0703.0NANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,jnj:MedicalDevices▇▇▅▁█1746.01629.01010.0-354.02025.0NA1392.03189.01497.0NA1267.0796.01579.0NA1383.0992.01563.0NA1526.0939.01576.0NA835.01584.02221.0NA3399.01703.0NANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,jnj:Pharmaceutical▅█▁▅▃4356.05223.03439.04514.03834.0NA-222.03677.02331.0NA2876.03651.03666.0NA2857.03414.03663.0NA3309.03687.03344.0NA2732.04122.02962.0NA3247.03469.0NANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax ▄▁▄▃█130.0-595.0175.0-39.0970.0NA-33.060.0-206.0NA96.0-164.014.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherComprehensiveIncomeLossNetOfTax ▆▅▇▇▅▅▄▇▅▄▆▁▇▄▆█▆▁▅▅▇228.0-86.0595.0710.0-352.0-358.0-564.0548.0-295.0-575.0130.0-2169.0823.0-452.0487.01288.0379.0-2186.0-8.0-316.0774.0NA-807.01246.0-2578.0-5340.0-2375.0-362.0215.02486.01464.0-121.0-879.0-885.01279.0-1664.01092.0NANANANANANANANANANANANA
us-gaap:OtherNonoperatingIncomeExpense ▇▇▅▆▇▆▁█▆▅▆▆▆▆▆▅▆▆▆▅▆488.0882.0-1200.0-24.0679.0-16.0-4214.01683.022.0-978.0-3.0-364.0-60.09.0236.0-588.0160.0-20.054.0-557.039.0NA-420.0931.0348.0-963.01345.0-226.0-86.0-868.0-943.0-172.0-515.0-319.090.0-2008.0611.0-2858.0308.0-206.013.0-1100.0292.0-18.01594.0NANANANA
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost ▇▆▅▄▃▆▄▄▅▆▃▄▃█▃▂▁▄▂▂▁3394.03178.02840.02707.02580.03232.02599.02666.02858.03224.02508.02639.02404.03635.02574.02285.02060.02640.02178.02264.02013.0NA2154.02129.01899.02635.02023.02005.01831.02411.02042.01946.01784.02331.01923.01766.01645.02155.01773.01882.01738.01982.01657.01648.01557.0NANANANA
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax █▇▆▄▆▆▆▆▅▆▆▆▅▅▅▄▃▄▃▄▃▃▃▃▃▄▄▅▄▄▃▃▃▃▃▂▂▂▂▂▂▂▁▁▂▂▁▁▁23312.022321.021082.018336.020691.020747.020729.020562.020021.020394.020348.020830.020009.020195.019650.018839.017766.018106.017820.018482.017482.017811.017102.017787.017374.018254.018467.019495.018115.018355.017575.017877.017505.017558.017052.016475.016139.016255.016005.016597.016173.015644.014982.015330.015631.016551.015081.015239.015026.0
us-gaap:Revenues █▇▆▄▆▆▆▆▅▆▆▆▅▅▅▄▃▄▃▄▃▃▃▃▃▄▄▅▄▄▃▃▃▃▃▂▂▂▂▂▂▂▁▁▂▂▁▁▁23312.022321.021082.018336.020691.020747.020729.020562.020021.020394.020348.020830.020009.020195.019650.018839.017766.018106.017820.018482.017482.017811.017102.017787.017374.018254.018467.019495.018115.018355.017575.017877.017505.017558.017052.016475.016139.016255.016005.016597.016173.015644.014982.015330.015631.016551.015081.015239.015026.0
us-gaap:SellingGeneralAndAdministrativeExpense █▅▅▃▄█▄▅▄█▅▆▄█▅▄▁▄▁▃▁6073.05432.05431.04993.05203.06039.05374.05546.05219.05991.05543.05743.05263.06025.05396.05262.04737.05309.04772.05176.04688.0NA5081.05384.04847.05822.05468.05481.05183.05917.05314.05376.05223.05661.05228.04965.05015.05458.05240.05215.05056.05180.04709.04756.04779.0NANANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:Assets ██▇▆▆▆▆▆▅▆▆▆▆▆▆▆▅▅▅▅▄▄▄▄▃▄▄▄▄▄▃▃▃▃▃▂▂▂▂▂▁▁176440.0172557.0170693.0158380.0155017.0157728.0155521.0155117.0150027.0152954.0155703.0155365.0156625.0157303.0155658.0152807.0144918.0141208.0140369.0139814.0136231.0133411.0133266.0132036.0128590.0131119.0132097.0135200.0133330.0132683.0126933.0124325.0121536.0121347.0118951.0115750.0116194.0113644.0111821.0112114.0108150.0102908.0NANANA94682.0NANANA
us-gaap:Liabilities ███▇▆▇▇▇▆▆▆▆▆▇▅▅▄▄▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▁▁▁▁106860.0106723.0106220.095402.093723.098257.097311.094332.091072.093202.091077.092476.093370.097143.081679.080885.074577.070790.067600.067341.063584.062261.061712.060905.060712.061367.055506.057152.056748.058630.057129.054660.054681.056521.055190.055316.054828.056564.050294.049982.048287.046329.0NANANA44094.0NANANA
us-gaap:LiabilitiesAndStockholdersEquity ██▇▆▆▆▆▆▅▆▆▆▆▆▆▆▅▅▅▅▄▄▄▄▃▄▄▄▄▄▃▃▃▃▃▂▂▂▂▂▁▁176440.0172557.0170693.0158380.0155017.0157728.0155521.0155117.0150027.0152954.0155703.0155365.0156625.0157303.0155658.0152807.0144918.0141208.0140369.0139814.0136231.0133411.0133266.0132036.0128590.0131119.0132097.0135200.0133330.0132683.0126933.0124325.0121536.0121347.0118951.0115750.0116194.0113644.0111821.0112114.0108150.0102908.0NANANA94682.0NANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:AssetsCurrent ▅▄▆▃▂▃▂▂▂▃▃▃▂▂▂▁▇█▇█▇▆▇▇▆▆▆▆▆▅▄▄▃▃▃▂▆▅▅▅▄▃53769.052533.057578.045892.044226.045274.044333.041799.041987.046033.047194.045438.042768.043088.041829.038789.063347.065032.063319.066291.062738.060210.063494.061001.058192.059311.059973.060119.057369.056407.052176.051273.047228.046116.044791.041615.057007.054316.053443.052673.049221.047307.0NANANA39541.0NANANA
us-gaap:CashAndCashEquivalentsAtCarryingValue ▂▂▄▁▃▃▃▂▂▄▃▃▂▄▃▂▅▄▄▄▂▂▂▁▁▂▂▂▄▅▃▃▃▃▃▂█▆▃▃▅▄▂▂▂▃14332.012671.018965.011174.015530.017305.016249.014376.014734.018107.016056.017569.014639.017824.015721.012598.020909.018972.018205.018640.013861.013732.013639.010639.011988.014523.013818.014236.019722.020927.017204.017307.014855.014911.015486.014042.030267.024542.015617.014974.022356.019355.014338.012713.013743.015810.0NANANA
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents ▄▂█▁▅▇▆▄▄▇▅14332.012671.018965.011174.015530.017305.016249.014376.014734.018107.016056.0NANA17824.0NANANA18972.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:MarketableSecuritiesCurrent ▄▄▄▃▂▁▁▁▁▁▂▁▁▁▁▁▆▇▇▇██▇▇▆▆10974.011948.011816.07961.02494.01982.01696.0902.0602.01580.03308.0570.0565.0472.0510.0255.018434.022935.022228.023944.025994.024644.023667.023315.019331.018566.0NANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:AccountsReceivableNetCurrent █████▇██▇▇▇▇▇▆▆▆▄▄▄▄▃▂▃▄▃▃▃▄▄▄▄▃▃▃▃▃▃▂▂▃▂▁14871.014938.014579.014645.014874.014481.014801.014653.014115.014098.014048.014111.014166.013490.013155.013283.012300.011699.011798.012062.011406.010734.011366.011968.011533.010985.011615.012257.012116.011713.012027.011614.011515.011309.011175.010992.010982.010581.010552.010982.010861.09774.0NANANA9646.0NANANA
us-gaap:InventoryNet ██▇▇▆▆▇▇▆▆▆▆▆▆▇▇▆▅▆▆▅▅▅▅▅▅▆▅▅▅▅▅▄▄▅▄▃▂▃▃▂▁10100.09952.09599.09424.08868.09020.09173.09263.09086.08599.08678.08810.09014.08765.09521.09699.08878.08144.08488.08523.08170.08053.08206.08298.08085.08184.08419.08155.08009.07878.08124.07822.07691.07495.07809.07697.06800.06285.06428.06413.06200.05378.0NANANA5180.0NANANA
us-gaap:PrepaidExpenseAndOtherAssetsCurrent ▆▄▂▂▂▂▁▂▂▃▄▂▃▂▄▄▃▅▂▅▅▄▄▄▇▆▄███▅▆▅▄▃▄▃▃▄▅3492.03024.02528.02588.02358.02392.02220.02411.02599.02699.02896.02569.02641.02537.02922.02954.02826.03282.02600.03122.03307.03047.03010.03058.03731.03486.03107.03982.03932.04003.03312.03425.03260.03084.02789.02894.02683.02633.03056.03290.0NA2273.0NANANANANANANA
us-gaap:Land NANANANANA854.0NANANA807.0NANANA829.0NANANA753.0NANANA780.0NANANA833.0NANANA885.0NANANA793.0NANANA754.0NANANA738.0NANANA714.0NANANA
us-gaap:MachineryAndEquipmentGross NANANANANA26964.0NANANA25992.0NANANA25949.0NANANA23554.0NANANA22511.0NANANA22206.0NANANA22527.0NANANA21075.0NANANA19182.0NANANA18032.0NANANA17153.0NANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
 us-gaap:NoncurrentAssets us-gaap:ConsolidationItems us-gaap:OperatingSegmentsNANANANANA97891.0NANANA94035.0NANANA100996.0NANANA64403.0NANANA62150.0NANANA64042.0NANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:NoncurrentAssets us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:CorporateNonSegment,jnj:GeneralCorporateNANANANANA1049.0NANANA1064.0NANANA1143.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:NoncurrentAssets us-gaap:ConsolidationItems,us-gaap:StatementGeographical us-gaap:OperatingSegments,country:USNANANANANA41528.0NANANA37117.0NANANA38556.0NANANA36934.0NANANA36609.0NANANA36835.0NANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:NoncurrentAssets us-gaap:ConsolidationItems,us-gaap:StatementGeographical us-gaap:OperatingSegments,jnj:AsiaPacificAfricaNANANANANA5486.0NANANA2733.0NANANA2773.0NANANA2512.0NANANA2493.0NANANA2438.0NANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:NoncurrentAssets us-gaap:ConsolidationItems,us-gaap:StatementGeographical us-gaap:OperatingSegments,jnj:WesternHemisphereExcludingUSNANANANANA2862.0NANANA2752.0NANANA2990.0NANANA2961.0NANANA2881.0NANANA3210.0NANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:NoncurrentAssets us-gaap:ConsolidationItems,us-gaap:StatementGeographical us-gaap:OperatingSegments,srt:EuropeNANANANANA48015.0NANANA51433.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:NoncurrentAssets us-gaap:PropertyPlantAndEquipmentByType us-gaap:OtherIntangibleAssetsNANANANANA81282.0NANANA78064.0NANANA85134.0NANANA49681.0NANANA47393.0NANANA49054.0NANANA50745.0NANANA51176.0NANANANANANANANANANANANANANANA
 us-gaap:NoncurrentAssets us-gaap:PropertyPlantAndEquipmentByType us-gaap:PropertyPlantAndEquipmentNANANANANA17658.0NANANA17035.0NANANA17005.0NANANA15912.0NANANA15905.0NANANA16126.0NANANA16710.0NANANA16097.0NANANANANANANANANANANANANANANA
us-gaap:PropertyPlantAndEquipmentGross ██▇▇▆▆▆▆▆▆▆▆▆▆▅▅▄▄▄▄▄▄▃▃▃▄▄▄▃▄▄▃▃▃▃▂▂▂▂▂▂▁47201.046430.045162.044056.043247.043332.042625.042905.042262.041851.041520.041293.041996.041466.040928.040075.038696.037773.038373.037779.037430.036648.036397.036112.035403.036685.036448.036947.036248.037133.036432.035401.034695.034654.034082.033297.032550.031829.031736.032435.031805.030426.0NANANA29251.0NANANA
us-gaap:ConstructionInProgressGross NANANANANA3637.0NANANA3876.0NANANA3448.0NANANA3354.0NANANA3528.0NANANA3600.0NANANA3298.0NANANA2740.0NANANA2504.0NANANA2577.0NANANA2521.0NANANA
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment ██▇▇▆▆▆▆▆▆▆▆▆▆▆▅▅▄▅▄▄▄▄▄▃▄▄▄▃▄▃▃▃▂▂▂▂▂▂▂▁▁28569.028063.027307.026458.025846.025674.025577.025657.025262.024816.024891.024661.024956.024461.024300.023617.022505.021861.022278.021807.021466.020743.020846.020529.020039.020559.020644.020792.020252.020423.020305.019607.018974.018557.018237.017675.017726.017090.017101.017461.016721.015873.0NANANA14492.0NANANA
us-gaap:AmortizationOfIntangibleAssets ███▇▇█▇▇▇▇▇▇▇▇▇▃▁▁▁▁▁1200.01200.01200.01100.01100.01200.01100.01100.01100.01100.01100.01100.01100.01114.01077.0480.0329.0305.0319.0294.0282.0NA293.0307.0312.0365.0335.0347.0351.0383.0327.0318.0335.0280.0378.0283.0205.0NANANANANANANANANANANANA
us-gaap:PropertyPlantAndEquipmentNet ██▇▆▆▆▅▆▅▅▅▅▅▅▅▄▄▃▄▃▃▃▃▃▂▄▃▄▃▅▄▃▃▄▃▃▁▁▁▂▂▁18632.018367.017855.017598.017401.017658.017048.017248.017000.017035.016629.016632.017040.017005.016628.016458.016191.015912.016095.015972.015964.015905.015551.015583.015364.016126.015804.016155.015996.016710.016127.015794.015721.016097.015845.015622.014824.014739.014635.014974.015084.014553.0NANANA14759.0NANANA
us-gaap:Goodwill ██▇▇▇▇▇▇▇▆▆▆▆▇▆▆▄▄▄▃▃▃▃▃▃▃▃▃▃▄▄▃▃▃▃▃▁▁▁▁▁▁35819.035688.034307.033890.033471.033639.033291.033661.031450.030453.030702.030346.031149.031906.031308.031234.024844.022805.023171.022104.021848.021629.021279.021493.021345.021832.021636.021989.022178.022798.022852.022337.022349.022424.021777.021412.016339.016138.016049.016243.016126.015294.0NANANA14862.0NANANA
us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill ██▄▄▄▄▃▃▁▂▂▃▃▃▄▄▃▃▃▃▃▃▃▃▃▃▂▂▂▂▂▁▁▁▁▂▁▁▁▁▂▁17841.017849.012695.012734.012625.011569.011165.011262.08303.09190.09228.010356.010586.011283.011678.011689.010469.010331.010425.010478.010582.010443.010275.010399.010310.010105.08746.08724.08768.08774.09138.08344.08385.08553.08478.08950.07998.07883.07901.08116.09172.07891.0NANANA7675.0NANANA
us-gaap:IntangibleAssetsNetExcludingGoodwill ▇▇▇▇▇▇▇▇▇▇▇▇████▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▁▁▁▁▁▁50244.051110.047006.047413.047338.047643.047846.049332.046898.047611.048637.050056.052365.053228.054569.054942.029466.026876.027642.025694.025840.025764.025988.027017.027025.027222.026304.027122.027643.027947.028467.027704.028009.028752.028790.029199.018157.018138.018225.018378.018687.016716.0NANANA16323.0NANANA
 us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:FiniteLivedIntangibleAssetsByMajorClass jnj:PatentsAndTrademarks▆▆▆▆▆▆▆▇▇▇▇▇████▂▂▂▁▁▁▁▁▁▁▁▁▁▁▁▁▁▂▂▂▁▁20806.021499.022283.022479.022357.023480.023956.025082.025415.025410.026401.026556.028386.029204.029947.030258.06085.05445.05798.03659.03472.03554.03611.04111.04199.04374.04377.04617.04899.05018.05164.05231.05326.05474.05557.05582.05008.04971.0NANANANANANANANANANANA
 us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:FiniteLivedIntangibleAssetsByMajorClass us-gaap:OtherIntangibleAssets▆▆▆▆▆▆▇▇▇▇▇▇▇▇▇▇▇▅▆▆▆▆▆▆▆▇▇▇▇███████▁▁11597.011762.012028.012200.012356.012594.012725.012988.013180.013011.013008.013144.013393.012741.012944.012995.012912.011100.011419.011557.011786.011767.012102.012507.012516.012743.013181.013781.013976.014155.014165.014129.014298.014725.014755.014667.05151.05284.0NANANANANANANANANANANA
 us-gaap:IntangibleAssetsNetIncludingGoodwill us-gaap:BusinessAcquisition,us-gaap:FiniteLivedIntangibleAssetsByMajorClass jnj:A2020Acquisitions,us-gaap:InProcessResearchAndDevelopmentNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:DeferredTaxAssetsLiabilitiesNet 600.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherAssetsNoncurrent █▇▆▆▅▆▅▅▅▄▄▄▄▅▅▅▄▄▄▃▄▄▃▃▃▂▅▇▇▅▁▁▃▂▃▃▃▃▃▄▃▃7172.06538.06131.05782.05042.05695.05307.05430.05159.04182.04465.04421.04518.04971.05021.05273.04690.04435.04245.03977.04163.04413.03804.03855.03605.03232.05033.06435.06459.04949.02715.02477.03723.03417.03521.03891.03956.03773.03905.04193.03705.03942.0NANANA3690.0NANANA
us-gaap:EquitySecuritiesFvNi █▇▅▇▃▅▃▄▃▁1678.01452.01140.01488.0826.01148.0863.0963.0830.0511.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:AccountsPayableCurrent ██▅▄▅█▆▅▅▆▅▄▄▅▄▃▃▅▃▃▃▄▃▃▄▆▄▃▃▃▃▂▂▂▂▁▁▂▂▂▂▂8704.08503.07044.06765.07411.08544.07491.06912.06923.07537.07000.06516.06443.07310.06390.06135.06082.06918.05971.06061.05965.06668.05928.06140.06719.07633.06603.06193.06113.06266.06055.05687.05372.05831.05344.05145.05085.05725.05730.05689.05701.05623.0NANANA5541.0NANANA
us-gaap:AccruedIncomeTaxesCurrent ▃▆▅▅▆▇█▅▃▂▃▂▅▆▃▂▃▃▂▂▃▂▃▂▄▁▅▃▂▂▅▃▃▃▄▄▂▂▄▂▃▁1200.01877.01666.01632.01930.02266.02505.01701.01025.0818.01096.0928.01559.01854.01183.0759.01133.0971.0798.0690.0968.0750.0931.0916.01243.0500.01535.01055.0862.0770.01711.0956.01178.01064.01502.01259.0914.0854.01336.0808.01007.0578.0NANANA442.0NANANA
us-gaap:AccruedLiabilitiesCurrent ▆█▅▅▄▅▅▄▄▄▂▃▃▃▂▃▂▂▂▂▂▂▂▂▂▃▃▃▄▄▃▃▃▃▃▃▁▁▁▁▁▁10485.013223.09629.08940.08384.09715.09004.08297.07946.07601.06044.06394.06535.07304.05897.06076.05262.05635.05283.05650.04996.05411.05062.05319.05575.06553.06188.07178.07710.07685.06921.06646.06904.07299.06498.06533.04369.04608.04136.04405.04093.04100.0NANANA4625.0NANANA
us-gaap:DebtCurrent NANANANANA1200.0NANANA2800.0NANANA3900.0NANANA4700.0NANANA7000.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LiabilitiesCurrent ▇█▇▇▅▆▆▅▄▅▃▃▃▄▅▄▂▃▂▁▁▃▃▂▂▂▂▂▂▃▃▂▂▂▂▂▁▂▁▁▂▂38721.040932.038847.036772.033689.035964.035162.031353.029111.031230.027437.027488.027081.030537.031806.028872.025119.026287.023230.021536.022134.027747.025260.024512.023836.025085.022982.024359.023840.025675.025835.023767.022524.024262.023935.023848.021198.022811.021686.020985.024011.023072.0NANANA21731.0NANANA
 us-gaap:LongTermDebtCurrent us-gaap:FairValueByMeasurementBasis us-gaap:CarryingReportedAmountFairValueDisclosureNANANANANA1100.0NANANA2636.0NANANA1499.0NANANA1704.0NANANA2104.0NANANA7.0NANANA1769.0NANANA1512.0NANANANANANANANANANANANANANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
 us-gaap:LongTermDebt us-gaap:BusinessAcquisition,us-gaap:LongtermDebtType jnj:Idorsia,us-gaap:ConvertibleDebtNANANANANA500.0NANANA500.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A0.250NotesDue2022NANANANANA1108.0NANANA1137.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A0.650NotesDue2024NANANANANA829.0NANANA851.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A1.150NotesDue2028NANANANANA825.0NANANA847.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A1.650NotesDue2035NANANANANA1649.0NANANA1693.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A1.65Notesdue2021NANANANANA999.0NANANA998.0NANANA998.0NANANA997.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A2.05Notesdue2023NANANANANA498.0NANANA498.0NANANA498.0NANANA497.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A2.25Notesdue2022NANANANANA998.0NANANA996.0NANANA995.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A2.45Notesdue2021NANANANANA349.0NANANA349.0NANANA349.0NANANA348.0NANANA349.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A2.45Notesdue2026NANANANANA1993.0NANANA1992.0NANANA1990.0NANANA1989.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A2.625Notesdue2025NANANANANA748.0NANANA748.0NANANA747.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A2.900Notesdue2028NANANANANA1494.0NANANA1493.0NANANA1492.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A2.95Notesdue2027NANANANANA996.0NANANA996.0NANANA995.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A3.375Notesdue2023NANANANANA804.0NANANA805.0NANANA806.0NANANA807.0NANANA811.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A3.400Notesdue2038NANANANANA991.0NANANA990.0NANANA990.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A3.500Notesdue2048NANANANANA742.0NANANA742.0NANANA742.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A3.55Notesdue2021NANANANANA449.0NANANA449.0NANANA448.0NANANA447.0NANANA448.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A3.55Notesdue2036NANANANANA989.0NANANA988.0NANANA987.0NANANA987.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A3.625Notesdue2037NANANANANA1487.0NANANA1486.0NANANA1486.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A3.70Notesdue2046NANANANANA1973.0NANANA1972.0NANANA1971.0NANANA1970.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A3.75Notesdue2047NANANANANA991.0NANANA991.0NANANA990.0NANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A4.375Notesdue2033NANANANANA855.0NANANA856.0NANANA856.0NANANA857.0NANANA864.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A4.50Debenturesdue2040NANANANANA539.0NANANA538.0NANANA538.0NANANA537.0NANANA540.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A4.50Notesdue2043NANANANANA495.0NANANA495.0NANANA495.0NANANA495.0NANANA499.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A4.85Notesdue2041NANANANANA297.0NANANA297.0NANANA296.0NANANA296.0NANANA298.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A4.95Debenturesdue2033NANANANANA498.0NANANA498.0NANANA498.0NANANA497.0NANANA500.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A5.50NotesDue2024NANANANANA645.0NANANA627.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A5.85Debenturesdue2038NANANANANA696.0NANANA696.0NANANA696.0NANANA695.0NANANA700.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A5.95Notesdue2037NANANANANA992.0NANANA991.0NANANA991.0NANANA990.0NANANA996.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A6.73Debenturesdue2023NANANANANA250.0NANANA250.0NANANA250.0NANANA249.0NANANA250.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument jnj:A6.95Notesdue2029NANANANANA297.0NANANA297.0NANANA296.0NANANA296.0NANANA297.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:DebtInstrument us-gaap:OtherDebtSecuritiesNANANANANA18.0NANANA24.0NANANA75.0NANANA77.0NANANA104.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:FairValueByMeasurementBasis us-gaap:CarryingReportedAmountFairValueDisclosureNANANANANA27594.0NANANA30320.0NANANA32174.0NANANA24146.0NANANA14961.0NANANA15129.0NANANA15097.0NANANA13001.0NANANANANANANANANANANANANANANA
 us-gaap:LongTermDebt us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName,us-gaap:LineOfCreditFacility,us-gaap:LongtermDebtType jnj:IdorsiaLTD,jnj:IdorsiaLTD,us-gaap:ConvertibleDebtNANA445.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LongTermDebtNoncurrent ▇▇█▆▆▆▆▇▇▇▇▇▇▇▆▆▆▅▅▆▄▂▂▂▃▃▂▂▂▂▁▁▂▂▂▂▂▂▂▂▁▁30310.030263.032680.025062.025393.026494.026919.027699.027660.027684.029480.029405.029837.030675.026675.027363.027015.022442.023546.024535.020233.012857.014073.014085.014938.015122.013152.013303.013343.013328.09748.09643.011363.011489.011428.011525.013010.012969.013031.013680.09255.09156.0NANANA8223.0NANANA
us-gaap:DeferredIncomeTaxLiabilitiesNet █▃▁▁▁▂▃▅▅▅9016.06507.05615.05532.05766.05958.06526.07725.07394.07506.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent NANANANANA10663.0NANANA9951.0NANANA10074.0NANA9609.09615.08217.08359.08591.08854.09515.09633.09750.09972.07551.07626.07700.07784.09038.08996.08978.09082.07904.08180.08236.08353.06215.06202.06125.06087.0NANANA6769.0NANANA
 us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanType us-gaap:OtherPostretirementBenefitPlansDefinedBenefitNANANANANA4564.0NANANA4019.0NANANA4073.0NANANA4215.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanType us-gaap:PensionPlansDefinedBenefitNANANANANA5425.0NANANA5229.0NANANA5251.0NANANA4624.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherLiabilitiesNoncurrent █▇▇▆▆▇▆▅▄▃▃▄▄▄▄▅▄▄▄▅▅▅▄▄▃▃▂▂▂▂▄▃▃▃▄▄▆▆▂▂▁▁12724.011941.012149.011034.010944.011734.011381.010102.08928.08589.08538.09281.08876.09017.09102.010117.09526.09536.09414.010062.09749.010241.09303.08973.08604.08034.07758.07373.07271.07854.08895.08569.08197.08552.09207.09487.010538.010631.07473.07227.07001.06567.0NANANA5947.0NANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest ▅▄▄▃▃▂▂▂▂▂▄▃▃▂▇▆▅▆▆▆▆▆▆▆▅▅███▇▅▅▄▄▃▂▃▁▃▃▂▁69580.065834.064473.062978.061294.059471.058210.060785.058955.059752.064626.062889.063255.060160.073979.071922.070341.070418.072769.072473.072647.071150.071554.071131.067878.069752.076591.078048.076582.074053.069804.069665.066855.064826.063761.060434.061366.057080.061527.062132.059863.056579.0NANANA50588.0NANANA
us-gaap:RetainedEarningsAccumulatedDeficit █▇▇▇▇▆▆▆▆▆▆▆▅▅▇▇▇▆▆▆▅▅▅▅▄▄▄▄▃▃▃▃▃▂▂▂▂▂▂▂▁▁120154.0116508.0114831.0113898.0112901.0110659.0109242.0109809.0106650.0106216.0107617.0106123.0104339.0101793.0114805.0113208.0111643.0110551.0108860.0106738.0104990.0103879.0102748.0101352.098656.097245.096560.093745.091387.089493.087703.089449.087242.085992.084880.083530.083103.081251.082634.080836.079515.077773.0NANANA70306.0NANANA
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax ▂▁▂▁▁▁▁▂▁▁▂▂▃▂▃▂▂▂▃▃▃▂▃▃▂▄▆▇▇▇▆▅▅▆▆▆▆▆▇██▇-15100.0-15328.0-14938.0-15533.0-16243.0-15891.0-15533.0-14969.0-15517.0-15222.0-14647.0-14777.0-12608.0-13199.0-12747.0-13234.0-14522.0-14901.0-12715.0-12707.0-12391.0-13165.0-12861.0-12054.0-13300.0-10722.0-5382.0-3007.0-2645.0-2860.0-5346.0-6810.0-6689.0-5810.0-4925.0-6204.0-4540.0-5632.0-3068.0-1192.0-2020.0-3531.0NANANA-3058.0NANANA
us-gaap:TreasuryStockValue ████████▇▇▆▆▆▆▆▆▅▅▄▄▃▃▃▃▃▂▂▁▁▁▁▁▁▂▂▂▃▃▃▃▃▃38594.038466.038540.038507.038484.038417.038619.037175.035298.034362.031464.031577.031596.031554.031199.031172.029900.028352.026496.024678.023072.022684.021453.021287.020598.019891.017707.015810.015280.015700.015673.016094.016818.018476.019314.020012.020317.021659.021159.020632.020752.020783.0NANANA19780.0NANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:NetCashProvidedByUsedInOperatingActivities ▅▃█▃▃▆▇▅▃▆▆▆▃▆▆▅▂▆▅▄▁5314.04074.08383.03452.03358.06398.07527.05948.03543.06244.06272.06079.03606.06105.06266.05772.02913.06653.05361.04990.01763.0NA6125.05200.02872.04365.04654.05529.03923.04139.05947.05051.02277.03376.04497.04728.02795.03451.04622.03909.02316.03824.05034.03837.03690.0NANANANA
us-gaap:NetCashProvidedByUsedInInvestingActivities ▇▇▅▃▇▆▆▆▆█▅▇▆▇▆▁▆▆▆█▆-419.0-185.0-4819.0-7522.0-581.0-1344.0-1645.0-1788.0-1417.02228.0-4269.0-201.0-925.0-505.0-1180.0-12247.0-936.0-2174.0-2372.01322.0-1537.0NA-1001.0-3554.0-1789.0-2922.0735.0-8092.0-2026.0-1578.0-1553.0-569.0-1403.0-2503.011398.0-17461.04056.06238.0-1590.0-10700.01440.0-1404.0-1875.0-2693.0-1882.0NANANANA
us-gaap:NetCashProvidedByUsedInFinancingActivities ▃▂█▅▂▃▃▂▂▁▃▃▁▃▄▄▅▃▃▄▅-3279.0-5125.04196.0-357.0-4315.0-4072.0-3893.0-4534.0-5516.0-6389.0-3477.0-2674.0-5970.0-3537.0-2069.0-1917.0-150.0-3464.0-3445.0-1464.0-178.0NA-1825.0-2503.0-3227.0-619.0-5716.0-2868.0-3057.01182.0-4519.0-1977.0-777.0-1471.0-14505.0-3403.0-1183.0-756.0-2232.0-639.0-825.02606.0-1699.0-2065.0-3822.0NANANANA
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect ▄▃█▁▂▄▅▃▂▅1661.0-1314.07791.0-4356.0-1775.01056.01873.0-358.0-3373.02051.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:DeferredIncomeTaxExpenseBenefit ▃▂▄▃▃▃▁▃▃▆▄▃▃█▃▃▃▂▄▃▄45.0-730.0190.0-482.054.0-350.0-1432.0-332.0-362.01900.0338.0-329.044.02813.0-335.0-45.0-27.0-556.0100.0-278.0393.0NA-51.0-261.0545.0144.0-296.098.0495.0-383.0-316.0-273.0365.0285.0187.0-1068.0557.013.0-345.0-500.0-4.0-288.040.0-356.0960.0NANANANA
us-gaap:DepreciationDepletionAndAmortization ██▇▇▇▇▇▇▇▇▇▇▇█▇▃▁▂▁▁▁1839.01894.01818.01726.01747.01816.01727.01705.01761.01735.01731.01717.01746.01869.01711.01150.0912.01055.0908.0900.0891.0NA929.0889.0895.0991.0939.0952.01013.01102.0976.0990.01036.01036.01005.0852.0773.0843.0783.0777.0755.0769.0725.0711.0734.0NANANANA
us-gaap:IncreaseDecreaseInAccountsReceivable ▂█▂▁▅▁▃▄▂▃▃▄▄▄▂▄▃▃▁▅▄-38.01604.0-80.0-292.0812.0-376.0329.0493.0-157.0145.051.0510.0479.0333.0-176.0380.096.0329.0-362.0709.0389.0NA-276.0421.0765.0-152.0-185.0158.0426.0-339.0324.0213.0434.0103.061.0-370.0215.0426.0-87.0-33.0609.0-378.030.026.0529.0NANANANA
us-gaap:IncreaseDecreaseInInventories ▅█▅▇▅▄▅▅▆▄▆▅▆▁▄▅▆▄▅▆▆123.0695.0147.0478.0159.0-147.01.054.0369.0-133.0286.0169.0322.0-774.0-228.053.0368.0-159.0-35.0253.0190.0NA182.0261.0276.022.0493.093.0512.0-177.0252.0259.0288.0-592.0-25.0169.0449.0-72.0167.0168.0452.0-1.0109.0-105.0193.0NANANANA
us-gaap:NetCashProvidedByUsedInOperatingActivities ▅▃█▃▃▆▇▅▃▆▆▆▃▆▆▅▂▆▅▄▁5314.04074.08383.03452.03358.06398.07527.05948.03543.06244.06272.06079.03606.06105.06266.05772.02913.06653.05361.04990.01763.0NA6125.05200.02872.04365.04654.05529.03923.04139.05947.05051.02277.03376.04497.04728.02795.03451.04622.03909.02316.03824.05034.03837.03690.0NANANANA
us-gaap:NetIncomeLoss ██▇▇█▇▆█▇▇▇▇▇▁▇▇▇▇▇▇▇▇▇▇▇▆▇▇▇▇▇▇▇▆▇▆▇▆▇▇▇▆▇▇▇▆▇▇▇6278.06197.03554.03626.05796.04010.01753.05607.03749.03042.03934.03954.04367.0-10713.03764.03827.04422.03814.04272.03997.04292.03215.03358.04516.04320.02521.04749.04326.04727.03519.02982.03833.03497.02567.02968.01408.03910.0218.03202.02776.03476.01942.03417.03449.04526.02206.03345.03208.03507.0
us-gaap:ShareBasedCompensation █▆▅▇▅▁▄▇▅▁▄▇▅▃▄▆▄▂▃▅▃354.0307.0256.0326.0263.0160.0245.0314.0258.0156.0242.0312.0268.0204.0236.0293.0229.0174.0225.0274.0205.0NA203.0270.0204.0146.0206.0242.0198.0144.0161.0229.0194.0147.0146.0196.0173.0137.0145.0187.0152.0140.0169.0148.0157.0NANANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:NetCashProvidedByUsedInInvestingActivities ▇▇▅▃▇▆▆▆▆█▅▇▆▇▆▁▆▆▆█▆-419.0-185.0-4819.0-7522.0-581.0-1344.0-1645.0-1788.0-1417.02228.0-4269.0-201.0-925.0-505.0-1180.0-12247.0-936.0-2174.0-2372.01322.0-1537.0NA-1001.0-3554.0-1789.0-2922.0735.0-8092.0-2026.0-1578.0-1553.0-569.0-1403.0-2503.011398.0-17461.04056.06238.0-1590.0-10700.01440.0-1404.0-1875.0-2693.0-1882.0NANANANA
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ▃▂▃▂▂▇▃▄▂█▃▄▂▇▃▂▁▆▃▃▂813.0677.0737.0662.0625.01260.0745.0837.0656.01318.0819.0875.0658.01240.0790.0689.0560.01093.0737.0757.0639.0NA789.0765.0543.01496.0751.0837.0630.01429.0809.0771.0586.01152.0682.0598.0502.01128.0711.0618.0436.0959.0528.0500.0397.0NANANANA
us-gaap:PaymentsToAcquireInvestments ▅▅▆▅▂▂▂▁▁▂▃▁▁▁▁▁▄▅█▆█6270.05994.07692.06487.02064.01236.01167.0787.0730.01471.03204.0403.0548.0355.0571.0677.04550.06273.010166.07449.010062.0NA7953.013651.07162.09129.08432.011925.05427.05340.05014.05018.03551.04597.03626.02813.02398.04438.08624.015784.01036.05109.03984.03449.03246.0NANANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
us-gaap:NetCashProvidedByUsedInFinancingActivities ▃▂█▅▂▃▃▂▂▁▃▃▁▃▄▄▅▃▃▄▅-3279.0-5125.04196.0-357.0-4315.0-4072.0-3893.0-4534.0-5516.0-6389.0-3477.0-2674.0-5970.0-3537.0-2069.0-1917.0-150.0-3464.0-3445.0-1464.0-178.0NA-1825.0-2503.0-3227.0-619.0-5716.0-2868.0-3057.01182.0-4519.0-1977.0-777.0-1471.0-14505.0-3403.0-1183.0-756.0-2232.0-639.0-825.02606.0-1699.0-2065.0-3822.0NANANANA
us-gaap:ProceedsFromIssuanceOfLongTermDebt ▁▁█0.01.07430.0NANA2.00.01.00.0-1.03.01.02.04527.01.00.04464.053.00.04516.07435.0NA0.00.03.02000.04.0-3.016.03500.045.00.06.029.010.04.02.0-1.067.04396.08.039.0NANANANANANANA
us-gaap:RepaymentsOfLongTermDebt ▃▅▃▁▁█▁▁▅▃▄▁▁▄▅▁▁▆▁▅▁450.01001.0551.00.011.01815.03.03.01002.0645.0901.01.08.0753.01009.013.02.01270.017.0922.014.0NA6.05.016.057.010.01756.021.062.027.01503.01.08.0786.0-20.030.04.07.02.03.011.09.04.08.0NANANANA
us-gaap:PaymentsForRepurchaseOfCommonStock ▂▃▂▂▄▂▄▅▅█▂▁▃▂▁▄▇▅▅▅▅631.01438.0483.0706.01711.0426.01628.02486.02206.03808.0471.0145.01444.0815.0311.01890.03342.02025.02203.02362.02389.0NA300.0896.02198.02743.02415.01192.0774.0488.03050.00.00.00.00.012852.067.0853.0743.0494.0435.01285.0732.0397.0383.0NANANANA
  2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29

Common Stock Shares Issued

us-gaap:CommonStockSharesIssued

us-gaap:CommonStockSharesIssued


Common
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931193119311931203119311931193119311931193119
Percentage of CommonStockSharesIssued100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Weighted Average Number Of Diluted Shares Outstanding

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding


Weighted
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value26712672266926652671266926912698272727212731273727412754278527942795280728122826286428742874288128932858281827982774277827812772278627962797
Percentage of WeightedAverageNumberOfDilutedSharesOutstanding100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Weighted Average Number Of Shares Outstanding Basic

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic


Weighted
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value26322631263226322633263526522660268326822682268426912706273127452757276827722782281428262826281828092790275727472736273727402738275127562755
Percentage of WeightedAverageNumberOfSharesOutstandingBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount


Antidilutive
Period End2021-04-042020-09-272020-06-282020-03-292019-09-292019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272012-07-012012-04-012011-10-022011-07-032011-04-032010-10-032010-07-042010-04-04
Value9.0202010.0190.00.0170.00.00.00.00.00.00.0205750515193866855
Percentage of AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount100.0100.0100.0100.0100.00.00.0100.00.00.00.00.00.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Basic

us-gaap:EarningsPerShareBasic

us-gaap:EarningsPerShareBasic


Earnings
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value2.382.351.351.382.21.520.672.111.411.141.471.471.63-3.991.41.421.631.411.561.461.561.161.211.631.550.91.691.531.671.251.061.361.250.931.080.511.430.081.171.011.270.711.241.251.640.81.211.161.27
Percentage of EarningsPerShareBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Diluted

us-gaap:EarningsPerShareDiluted

us-gaap:EarningsPerShareDiluted


Earnings
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value2.352.321.331.362.171.50.662.081.391.121.441.451.6-3.991.371.41.611.381.531.431.541.151.21.611.530.891.661.511.641.231.041.331.220.911.050.51.410.081.151.01.250.71.231.231.620.791.21.151.26
Percentage of EarningsPerShareDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Comprehensive Income Net Of Tax

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTax


Comprehensive
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-02
Value65066111414943365444118961553454406417855190425151154801426436815066255157621742-2819.0237439644942600544463712261816824247-256.05002-2346.01324
Percentage of ComprehensiveIncomeNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax27.927.419.723.626.35.729.917.320.08.625.921.627.227.023.919.929.014.932.410.0-15.412.920.327.332.725.320.815.09.624.9-1.631.0-14.48.3

Cost Of Goods And Services Sold

us-gaap:CostOfGoodsAndServicesSold

us-gaap:CostOfGoodsAndServicesSold


Cost
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-01
Value758770636972657970627134686769406615696165896927661472596925
Percentage of CostOfGoodsAndServicesSold100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax32.531.633.135.934.134.433.133.833.034.132.433.333.135.935.2

Gross Profit

us-gaap:GrossProfit

us-gaap:GrossProfit


Gross
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value15725152581411011757136291361313862136221340613433137591390313395129521274813016123801257212334131461215312138118781243012092124011306813456126601240012231123881195111555114551133211224109171093311425113951060410388107001110311239106471078910775
Percentage of GrossProfit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax67.568.466.964.165.965.666.966.267.065.967.666.766.964.164.969.169.769.469.271.169.568.169.569.969.667.970.869.069.967.669.669.368.365.867.268.869.567.268.368.870.567.869.369.871.067.970.670.871.7

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments


Income
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value666274294401394065094218164770414422312244234973548125604790474855754324528149045294375841225741557527036810562654242750366747934261310035952035504531841113422451022284219422062802604424542634643
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax28.633.320.921.531.520.37.934.222.115.321.723.927.412.724.425.231.423.929.626.530.321.124.132.332.114.836.928.929.915.020.926.824.317.721.112.431.32.025.720.627.914.228.227.540.215.728.128.030.9

Income Tax Expense Benefit

us-gaap:IncomeTaxExpenseBenefit

us-gaap:IncomeTaxExpenseBenefit


Income
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value3841232847314713208-106.0143467380489101911141327310269211153510100990710027641225125518220611300697-769.0685960764533966627113510090964610342868027711754
Percentage of IncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.65.54.01.73.41.0-0.57.03.40.42.44.95.665.75.24.96.52.85.74.95.74.56.97.21.011.26.73.8-4.23.95.44.43.05.73.87.00.65.73.96.41.85.45.011.2

Interest Expense

us-gaap:InterestExpense

us-gaap:InterestExpense


Interest
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value4063444525854883102250243253259274229227204184192190160123131138139130128136134105118125107135143147183134129125138108101108
Percentage of InterestExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.20.20.10.40.20.40.51.21.21.21.31.41.21.21.11.01.11.00.90.70.70.80.80.70.70.80.70.60.70.70.60.80.90.91.10.80.80.80.90.70.70.7

Litigation Settlement Expense

us-gaap:LitigationSettlementExpense us-gaap:StatementBusinessSegments

us-gaap:LitigationSettlementExpense

jnj:Consumer


Litigation
Period End2021-07-042020-09-272020-06-282019-12-292019-09-292019-06-30
Value1005006002000.0200
Percentage of LitigationSettlementExpense100.0100.0100.0100.00.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.42.43.31.00.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Consumer2.714.218.25.60.05.6

jnj:Pharmaceutical


Litigation
Period End2020-09-272020-03-292019-12-292019-09-292019-06-302019-03-312017-12-312016-04-032015-09-27
Value10001000.04000100300171360.0
Percentage of LitigationSettlementExpense200.00.00.00.050.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.70.50.019.30.51.50.10.80.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical8.80.90.036.80.92.90.21.70.0

Net Income Loss

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value6278619735543626579640101753560737493042393439544367-10713.03764382744223814427239974292321533584516432025214749432647273519298238333497256729681408391021832022776347619423417344945262206334532083507
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax26.927.816.919.828.019.38.527.318.714.919.319.021.8-53.019.220.324.921.124.021.624.618.119.625.424.913.825.722.226.119.217.021.420.014.617.48.524.21.320.016.721.512.422.822.529.013.322.221.123.3

us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value6278619735543626579640101753560737493042393439544367
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax26.927.816.919.828.019.38.527.318.714.919.319.021.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.0

Operating Income Loss

us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems

us-gaap:OperatingIncomeLoss

us-gaap:CorporateNonSegment


Operating
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value244211239252120176231147230303312328316247233293192256282252243249
Percentage of OperatingIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.00.91.11.40.60.81.10.71.11.51.61.71.71.41.31.61.11.51.61.51.31.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:CorporateNonSegment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OperatingSegments


Operating
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value6906764046404192662918237272456946535276579351185064582255145197548643786023582770535875
Percentage of OperatingIncomeLoss2830.33620.91941.41663.55524.21035.83148.13108.22023.01741.31856.71560.41602.52357.12366.51773.72857.31710.22135.82312.32902.52359.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.634.222.022.932.08.835.422.822.925.329.026.026.932.830.928.131.425.633.933.538.230.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OperatingIncomeLoss us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, jnj:Consumer


Operating
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value80478819132770653406741510829548878658596679571566811317644407703
Percentage of OperatingIncomeLoss329.5373.579.912.7641.7371.0175.8504.1221.7273.6175.6267.7208.2241.3291.4194.9294.8316.8112.4255.6167.5282.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.43.50.90.23.73.22.03.72.54.02.74.53.53.43.83.13.24.71.83.72.23.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments jnj:Consumer0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OperatingSegments, jnj:MedicalDevices


Operating
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value174616291010-354.020251392318914971267796157913839921563152693915768351584222133991703
Percentage of OperatingIncomeLoss715.6772.0422.6-140.51687.5790.91380.51018.4550.9262.7506.1421.6313.9632.8654.9320.5820.8326.2561.7881.31398.8683.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.57.34.8-1.99.86.715.57.56.23.87.97.05.38.88.65.19.04.98.912.818.48.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments jnj:MedicalDevices0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OperatingSegments, jnj:Pharmaceutical


Operating
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-29
Value43565223343945143834-222.03677233128763651366628573414366333093687334427324122296232473469
Percentage of OperatingIncomeLoss1785.22475.41438.91791.33195.0-126.11591.81585.71250.41205.01175.0871.01080.41483.01420.21258.41741.71067.21461.71175.41336.21393.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.723.416.324.618.5-1.117.911.614.117.518.314.518.120.618.619.919.116.023.217.017.617.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:OperatingSegments jnj:Pharmaceutical0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-01
Value130-595.0175-39.0970-33.060-206.096-164.014
Percentage of OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.6-2.70.8-0.24.7-0.20.3-1.00.5-0.80.1

Other Comprehensive Income Loss Net Of Tax

us-gaap:OtherComprehensiveIncomeLossNetOfTax

us-gaap:OtherComprehensiveIncomeLossNetOfTax


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-01
Value228-86.0595710-352.0-358.0-564.0548-295.0-575.0130-2169.0823-452.04871288379-2186.0-8.0-316.0774-807.01246-2578.0-5340.0-2375.0-362.021524861464-121.0-879.0-885.01279-1664.01092
Percentage of OtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.0-0.42.83.9-1.7-1.7-2.72.7-1.5-2.80.6-10.44.1-2.22.56.82.1-12.1-0.0-1.74.4-4.77.0-14.8-29.3-12.9-1.91.213.58.3-0.7-5.0-5.07.5-10.16.8

us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents

us-gaap:AccumulatedDefinedBenefitPlansAdjustment


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value234233197195195-1175.0136137169-565.0186185186-527.0120118119
Percentage of OtherComprehensiveIncomeLossNetOfTax102.6-270.933.127.5-55.4328.2-24.125.0-57.398.3143.1-8.522.6116.624.69.231.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.00.91.10.9-5.70.70.70.8-2.80.90.90.9-2.60.60.60.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedDefinedBenefitPlansAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedGainLossNetCashFlowHedgeParent


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-31
Value130-595.0175-39.097079-33.060-206.0
Percentage of OtherComprehensiveIncomeLossNetOfTax57.0691.929.4-5.5-275.6-22.15.910.969.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.6-2.70.8-0.24.70.4-0.20.3-1.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedGainLossNetCashFlowHedgeParent0.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss


Other
Period End2020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1.0-2.02.0-1.00.01.00.01.0-1.00.00.0-37.0-85.033-90.0
Percentage of OtherComprehensiveIncomeLossNetOfTax0.2-0.3-0.60.3-0.00.2-0.0-0.2-0.8-0.00.08.2-17.52.6-23.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.0-0.00.0-0.00.00.00.00.0-0.00.00.0-0.2-0.40.2-0.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedOtherComprehensiveIncome


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value228-86.0595710-352.0-358.0-564.0548-295.0-575.0130-2169.0823-452.04871288379
Percentage of OtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.0-0.42.83.9-1.7-1.7-2.72.7-1.5-2.80.6-10.44.1-2.22.56.82.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedTranslationAdjustment


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value-135.0276222556-1519.0739-667.0350-258.0200-151.0-2190.062399359843395
Percentage of OtherComprehensiveIncomeLossNetOfTax-59.2-320.937.378.3431.5-206.4118.363.987.5-34.8-116.2101.075.7-21.973.765.5104.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-0.61.21.13.0-7.33.6-3.21.7-1.31.0-0.7-10.53.10.51.84.52.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccumulatedTranslationAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Other Nonoperating Income Expense

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:OtherNonoperatingIncomeExpense


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value488882-1200.0-24.0679-16.0-4214.0168322-978.0-3.0-364.0-60.09.0236-588.0160-20.054-557.039-420.0931348-963.01345-226.0-86.0-868.0-943.0-172.0-515.0-319.090-2008.0611-2858.0308-206.013-1100.0292-18.01594
Percentage of OtherNonoperatingIncomeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.14.0-5.7-0.13.3-0.1-20.38.20.1-4.8-0.0-1.7-0.30.01.2-3.10.9-0.10.3-3.00.2-2.55.22.0-5.37.3-1.2-0.5-4.7-5.4-1.0-2.9-1.80.5-12.23.8-17.61.9-1.20.1-7.01.9-0.110.2

Research And Development Expense Excluding Acquired In Process Cost

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost


Research
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value33943178284027072580323225992666285832242508263924043635257422852060264021782264201321542129189926352023200518312411204219461784233119231766164521551773188217381982165716481557
Percentage of ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.614.213.514.812.515.612.513.014.315.812.312.712.018.013.112.111.614.612.212.211.512.612.010.914.411.010.310.113.111.610.910.213.311.310.710.213.311.111.310.712.711.110.810.0

Revenue From Contract With Customer Excluding Assessed Tax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value23312223212108218336206912074720729205622002120394203482083020009201951965018839177661810617820184821748217811171021778717374182541846719495181151835517575178771750517558170521647516139162551600516597161731564414982153301563116551150811523915026
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments

jnj:BabyCare, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value387389393356361421417443394473472456457490477494455
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.71.91.91.72.02.02.22.02.32.32.22.32.42.42.62.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.71.91.91.72.02.02.22.02.32.32.22.32.42.42.62.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:BabyCare jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Beauty, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1170116311491149111711501151120210901111107811091084111010331076981
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.05.25.56.35.45.55.65.85.45.45.35.35.45.55.35.75.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.05.25.56.35.45.55.65.85.45.45.35.35.45.55.35.75.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Beauty jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTC, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1307117511421348119510981064108711481048106610721105100210061013
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.65.35.46.55.85.35.25.45.65.25.15.45.55.15.35.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.65.35.46.55.85.35.25.45.65.25.15.45.55.15.35.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTC jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OralCare, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value426417412397395393379389367399384393379393382394362
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.81.92.02.21.91.91.81.91.82.01.91.91.91.91.92.12.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.81.92.02.21.91.91.81.91.82.01.91.91.91.91.92.12.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OralCare jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WomensHealth, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value230222230202232253255253225257269280243262270276242
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.01.11.11.11.21.21.21.11.31.31.31.21.31.41.51.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.01.11.11.11.21.21.21.11.31.31.31.21.31.41.51.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WomensHealth jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WoundCareandOther, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value216177189185171155168193155148164200163180192232175
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.80.91.00.80.70.80.90.80.70.81.00.80.91.01.21.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.80.91.00.80.70.80.90.80.70.81.00.80.91.01.21.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WoundCareandOther jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementBusinessSegments, us-gaap:Subsegments

jnj:ADVANCED, jnj:MedicalDevices, jnj:Surgery


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value116811181000775948107610101029980105597610059661023923933877
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.05.04.74.24.65.24.95.04.95.24.84.84.85.14.75.04.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.05.04.74.24.65.24.95.04.95.24.84.84.85.14.75.04.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ADVANCED jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONCERTAMethylphenidate, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value161171149149171152193137214150157183173203198181209
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.80.70.80.80.70.90.71.10.70.80.90.91.01.01.01.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.80.70.80.80.70.90.71.10.70.80.90.91.01.01.01.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONCERTAMethylphenidate jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONTACTLENSESOTHER, jnj:MedicalDevices, jnj:Vision


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-02
Value868857830554814833893842824816835844807800800753
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.73.83.93.03.94.04.34.14.14.04.14.14.04.04.14.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.73.83.93.03.94.04.34.14.14.04.14.14.04.04.14.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONTACTLENSESOTHER jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:COVID19, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-04
Value164100
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:COVID19 jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0

jnj:DARZALEX, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value143313651099901937830765774629584498511432371317299255
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.16.15.24.94.54.03.73.83.12.92.42.52.21.81.61.61.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.16.15.24.94.54.03.73.83.12.92.42.52.21.81.61.61.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:DARZALEX jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:EDURANTrilpivirine, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value262243236256224222218210211193202211210192194179149
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.11.11.41.11.11.11.01.10.91.01.01.01.01.01.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.11.11.41.11.11.11.01.10.91.01.01.01.01.01.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:EDURANTrilpivirine jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ERLEADA, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-31
Value302261206170143866961
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.21.00.90.70.40.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.21.00.90.70.40.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ERLEADA jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0

jnj:GENERAL, jnj:MedicalDevices, jnj:Surgery


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1354125411527751153117111011119108911811080116911271170110511141074
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.85.65.54.25.65.65.35.45.45.85.35.65.65.85.65.96.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.85.65.54.25.65.65.35.45.45.85.35.65.65.85.65.96.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:GENERAL jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:HIPS, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value392357345226337377336364361365330360363364328350352
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.61.61.21.61.81.61.81.81.81.61.71.81.81.71.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.71.61.61.21.61.81.61.81.81.81.61.71.81.81.71.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:HIPS jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IMBRUVICA, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1116112510319491031875921831784703705620587522512450409
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.85.04.95.25.04.24.44.03.93.43.53.02.92.62.62.42.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.85.04.95.25.04.24.44.03.93.43.53.02.92.62.62.42.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:IMBRUVICA jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1024965926879883871851818790763749720696693643629604
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.44.34.44.84.34.24.14.03.93.73.73.53.53.43.33.33.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.44.34.44.84.34.24.14.03.93.73.73.53.53.43.33.33.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVOKANAINVOKAMET, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value160150224179175177179177202228190215248267265295284
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.71.11.00.80.90.90.91.01.10.91.01.21.31.31.61.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.71.11.00.80.90.90.91.01.10.91.01.21.31.31.61.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVOKANAINVOKAMET jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:KNEES, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value350317308174343395344372369392341382387397343385398
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.41.50.91.71.91.71.81.81.91.71.81.92.01.72.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.41.50.91.71.91.71.81.81.91.71.81.92.01.72.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:KNEES jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OPSUMIT, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value463450392406389326347348306323310311271269259450.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.02.01.92.21.91.61.71.71.51.61.51.51.41.31.30.20.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.02.01.92.21.91.61.71.71.51.61.51.51.41.31.30.20.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OPSUMIT jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

jnj:OTHERNEUROSCIENCE, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value468428377406435383384401446409409437494431463450477
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.01.91.82.22.11.81.92.02.22.02.02.12.52.12.42.42.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.01.91.82.22.11.81.92.02.22.02.02.12.52.12.42.42.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTHERNEUROSCIENCE jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value271261294312302286325368374333334388415413447413431
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.21.41.71.51.41.61.81.91.61.61.92.12.02.32.22.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.21.41.71.51.41.61.81.91.61.61.92.12.02.32.22.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value9510597101106323137353936403444395.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.50.60.50.20.10.20.20.20.20.20.20.20.20.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.50.60.50.20.10.20.20.20.20.20.20.20.20.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

jnj:OtherImmunology, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-01
Value7.08.03.03.03.02.02.03.03.0-366.01733.02.0-14.022
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.0-1.80.90.00.0-0.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.0-1.80.90.00.0-0.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherImmunology jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherInfectiousDiseases, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value9811710211311699113117112114131146142138152159170
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.50.60.60.50.50.60.60.60.60.70.70.70.80.81.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.50.50.60.60.50.50.60.60.60.60.70.70.70.80.81.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherInfectiousDiseases jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherOncology, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value12018298106104220186170163164156136134120127130127
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.80.50.60.51.10.90.80.80.80.80.70.70.60.60.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.80.50.60.51.10.90.80.80.80.80.70.70.60.60.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherOncology jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value505546526510579544508535523495490492478470467454430
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.42.52.82.82.62.52.62.62.42.42.42.42.32.42.42.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.42.52.82.82.62.52.62.62.42.42.42.42.32.42.42.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PROCRITEPREX, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value127127132136155183198183226221255236276232238255247
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.60.70.70.91.00.91.11.11.31.11.41.11.21.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.60.70.70.91.00.91.11.11.31.11.41.11.21.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PROCRITEPREX jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:RISPERDALCONSTA, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value155157152153170160167182179178175188196197194207207
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.70.70.80.80.80.80.90.90.90.90.91.01.01.01.11.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.70.70.80.80.80.80.90.90.90.90.91.01.01.01.11.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:RISPERDALCONSTA jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Remicade, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value888777921935990103511361107110212381379132013891466164715301672
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.83.54.45.14.85.05.55.45.56.16.86.36.97.38.48.19.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.83.54.45.14.85.05.55.45.56.16.86.36.97.38.48.19.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Remicade jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SPINEOTHER, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value776706745499703817778818788831786845804856871915883
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.23.52.73.43.93.84.03.94.13.94.14.04.24.44.95.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.23.52.73.43.93.84.03.94.13.94.14.04.24.44.95.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SPINEOTHER jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SURGICAL, jnj:MedicalDevices, jnj:Vision


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-02
Value314288251141253309299319305317297329308319291302
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.31.20.81.21.51.41.61.51.61.51.61.51.61.51.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.31.20.81.21.51.41.61.51.61.51.61.51.61.51.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SURGICAL jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SimponiSimponiAria, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value584562592546529515586563524482536548518490476439428
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.52.83.02.62.52.82.72.62.42.62.62.62.42.42.32.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.52.83.02.62.52.82.72.62.42.62.62.62.42.42.32.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SimponiSimponiAria jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Stelara, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value227421481947169718191700169815581405144413101341106110811124983823
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.89.69.29.38.88.28.27.67.07.16.46.45.35.45.75.24.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.89.69.29.38.88.28.27.67.07.16.46.45.35.45.75.24.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Stelara jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:TRAUMA, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value710733685553654686677672685674654675696669662643642
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.03.33.23.03.23.33.33.33.43.33.23.23.53.33.43.43.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.03.33.23.03.23.33.33.33.43.33.23.23.53.33.43.43.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:TRAUMA jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Tremfya, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value47941832734229627029023521717517112672
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.11.91.61.91.41.31.41.11.10.90.80.60.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.11.91.61.91.41.31.41.11.10.90.80.60.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Tremfya jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:UPTRAVI, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value3133052602822502082102031981811711711401301249.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.41.21.51.21.01.01.01.00.90.80.80.70.60.60.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.41.21.51.21.01.01.01.00.90.80.80.70.60.60.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:UPTRAVI jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

jnj:VELCADE, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value10598108115149224263252271280313271273290280
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.60.71.11.31.21.31.31.61.31.41.51.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.60.71.11.31.21.31.31.61.31.41.51.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:VELCADE jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Xarelto, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value569589630559527609613549542608612679578710635642513
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.42.63.03.02.52.93.02.72.73.03.03.32.93.53.23.42.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.42.63.03.02.52.93.02.72.73.03.03.32.93.53.23.42.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Xarelto jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ZYTIGA, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value563638590568690677741698679786958909845755669558523
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.42.92.83.13.33.33.63.43.43.94.74.44.23.73.43.02.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.42.92.83.13.33.33.63.43.43.94.74.44.23.73.43.02.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ZYTIGA jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments

jnj:BabyCare, country:US, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value9796919692859199871161208997
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.50.40.40.40.50.40.60.60.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.50.40.40.40.50.40.60.60.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:BabyCare country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:BabyCare, us-gaap:NonUs, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value290293302260269336326344307357352367360
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.31.41.41.31.61.61.71.51.81.71.81.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.31.41.41.31.61.61.71.51.81.71.81.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:BabyCare us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Beauty, country:US, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value659634572170659582559663588612543637611
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.82.82.70.93.22.82.73.22.93.02.73.13.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.82.82.70.93.22.82.73.22.93.02.73.13.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Beauty country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Beauty, us-gaap:NonUs, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value511529577227458568592539502499535472473
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.42.71.22.22.72.92.62.52.42.62.32.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.42.71.22.22.72.92.62.52.42.62.32.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Beauty us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTC, country:US, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value675599601536689542477484507491440454465
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.92.72.92.93.32.62.32.42.52.42.22.22.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.92.72.92.93.32.62.32.42.52.42.22.22.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTC country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTC, us-gaap:NonUs, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value633575541471659653621580580657608612607
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.72.62.62.63.23.13.02.82.93.23.02.93.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.72.62.62.63.23.13.02.82.93.23.02.93.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTC us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OralCare, country:US, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value165163164627176159156155151165158157157
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.70.83.40.90.80.80.80.80.80.80.80.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.70.83.40.90.80.80.80.80.80.80.80.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OralCare country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OralCare, us-gaap:NonUs, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value260254248522219233223234216234226236222
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.11.22.81.11.11.11.11.11.11.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.11.22.81.11.11.11.11.11.11.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OralCare us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WomensHealth, country:US, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value3.03.03.03.04.03.03.03.03.03.03.04.03.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WomensHealth country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WomensHealth, us-gaap:NonUs, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value227219227199228250252250222254266276240
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.01.11.11.11.21.21.21.11.21.31.31.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.01.01.11.11.11.21.21.21.11.21.31.31.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WomensHealth us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WoundCareandOther, country:US, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value1531151251261199810913210292106135103
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.50.60.70.60.50.50.60.50.50.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.50.60.70.60.50.50.60.50.50.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WoundCareandOther country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WoundCareandOther, us-gaap:NonUs, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value64616459525759615356586560
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.30.30.30.30.30.30.30.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.30.30.30.30.30.30.30.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WoundCareandOther us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments, us-gaap:Subsegments

jnj:ADVANCED, country:US, jnj:MedicalDevices, jnj:Surgery


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value459405421277381428409396404441421402393
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.01.82.01.51.82.12.01.92.02.22.11.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.01.82.01.51.82.12.01.92.02.22.11.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ADVANCED country:US jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ADVANCED, us-gaap:NonUs, jnj:MedicalDevices, jnj:Surgery


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value708713579498567647602633576614555603573
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.03.22.72.72.73.12.93.12.93.02.72.92.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.03.22.72.72.73.12.93.12.93.02.72.92.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ADVANCED us-gaap:NonUs jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONCERTAMethylphenidate, country:US, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value35474355523784159738576866
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.20.30.30.20.40.10.50.20.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.20.30.30.20.40.10.50.20.30.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONCERTAMethylphenidate country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONCERTAMethylphenidate, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value12712310794118115109123116112100115107
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.50.50.60.60.50.60.60.50.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.60.50.50.60.60.50.60.60.50.50.60.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONCERTAMethylphenidate us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONTACTLENSESOTHER, country:US, jnj:MedicalDevices, jnj:Vision


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value352371375203346311339333321289319320309
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.71.81.11.71.51.61.61.61.41.61.51.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.71.81.11.71.51.61.61.61.41.61.51.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONTACTLENSESOTHER country:US jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:CONTACTLENSESOTHER, us-gaap:NonUs, jnj:MedicalDevices, jnj:Vision


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value517486455352467522555509502527516524498
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.22.21.92.32.52.72.52.52.62.52.52.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.22.22.21.92.32.52.72.52.52.62.52.52.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:CONTACTLENSESOTHER us-gaap:NonUs jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:COVID19, country:US, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-04
Value51100
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:COVID19 country:US jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0

jnj:COVID19, us-gaap:NonUs, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-04
Value113
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:COVID19 us-gaap:NonUs jnj:Pharmaceutical jnj:InfectiousDiseases100.0

jnj:DARZALEX, country:US, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value770691585492463444402369352323318298264
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.12.82.72.22.11.91.81.81.61.61.41.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.12.82.72.22.11.91.81.81.61.61.41.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:DARZALEX country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:DARZALEX, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value663674514409474385363405277261180213168
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.83.02.42.22.31.91.82.01.41.30.91.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.83.02.42.22.31.91.82.01.41.30.91.00.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:DARZALEX us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:EDURANTrilpivirine, country:US, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value9.010.01110.0121412121216131514
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.10.10.10.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.10.10.10.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:EDURANTrilpivirine country:US jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:EDURANTrilpivirine, us-gaap:NonUs, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value253233226246212209206198199177189196196
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.01.11.31.01.01.01.01.00.90.90.91.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.01.11.31.01.01.01.01.00.90.90.91.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:EDURANTrilpivirine us-gaap:NonUs jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ERLEADA, country:US, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-31
Value193171152136119746258
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.80.70.70.60.40.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.80.80.70.70.60.40.30.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ERLEADA country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ERLEADA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-31
Value10990553324127.03.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.40.30.20.10.10.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.40.30.20.10.10.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ERLEADA us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0

jnj:GENERAL, country:US, jnj:MedicalDevices, jnj:Surgery


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value576493492213463451443443425469423436423
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.22.31.22.22.22.12.22.12.32.12.12.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.22.31.22.22.22.12.22.12.32.12.12.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:GENERAL country:US jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:GENERAL, us-gaap:NonUs, jnj:MedicalDevices, jnj:Surgery


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value779761660562690720659674665712657733704
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.43.13.13.33.53.23.33.33.53.23.53.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.43.13.13.33.53.23.33.33.53.23.53.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:GENERAL us-gaap:NonUs jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:HIPS, country:US, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value234210221137206230204216213220201211209
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.00.91.00.71.01.11.01.11.11.11.01.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.00.91.00.71.01.11.01.11.11.11.01.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:HIPS country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:HIPS, us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value15914612488132147133147148145129149154
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.70.60.50.60.70.60.70.70.70.60.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.70.60.50.60.70.60.70.70.70.60.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:HIPS us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IMBRUVICA, country:US, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value454444450447432392447367349318334250227
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.92.02.12.42.11.92.21.81.71.61.61.21.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.92.02.12.42.11.92.21.81.71.61.61.21.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:IMBRUVICA country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IMBRUVICA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value662680581502599483475463435385371370360
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.83.02.82.72.92.32.32.32.21.91.81.81.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.83.02.82.72.92.32.32.32.21.91.81.81.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:IMBRUVICA us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA, country:US, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value645589585576544564554506483485468438400
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.82.62.83.12.62.72.72.52.42.42.32.12.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.82.62.83.12.62.72.72.52.42.42.32.12.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value380376341303339308297312307278281282296
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.71.61.71.61.51.41.51.51.41.41.41.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.71.61.71.61.51.41.51.51.41.41.41.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTA us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVOKANAINVOKAMET, country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value9687156132117125125132154188150169204
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.70.70.60.60.60.60.80.90.70.81.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.70.70.60.60.60.60.80.90.70.81.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVOKANAINVOKAMET country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:INVOKANAINVOKAMET, us-gaap:NonUs, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value64636847585255434940404644
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.30.30.30.30.20.20.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.30.30.30.30.20.20.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:INVOKANAINVOKAMET us-gaap:NonUs jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:KNEES, country:US, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value210185205108214239209218223239215229228
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.81.00.61.01.21.01.11.11.21.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.81.00.61.01.21.01.11.11.21.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:KNEES country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:KNEES, us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value14013210266130156136153146153126153159
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.60.50.40.60.80.70.70.70.80.60.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.60.50.40.60.80.70.70.70.80.60.70.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:KNEES us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OPSUMIT, country:US, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value290272244256229185206203172189182180149
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.21.21.41.10.91.01.00.90.90.90.90.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.21.21.41.10.91.01.00.90.90.90.90.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OPSUMIT country:US jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OPSUMIT, us-gaap:NonUs, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value172179148150160143140146133134128131122
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.80.70.80.80.70.70.70.70.70.60.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.80.70.80.80.70.70.70.70.70.60.60.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OPSUMIT us-gaap:NonUs jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTHERNEUROSCIENCE, country:US, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value91676075757068626660505376
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.30.40.40.30.30.30.30.30.20.30.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.30.40.40.30.30.30.30.30.20.30.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTHERNEUROSCIENCE country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OTHERNEUROSCIENCE, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value377361317331360314316340379349359384418
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.61.51.81.71.51.51.71.91.71.81.82.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.61.51.81.71.51.51.71.91.71.81.82.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OTHERNEUROSCIENCE us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value576075788578911071041028697132
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.40.40.40.40.40.50.50.50.40.50.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.30.40.40.40.40.40.50.50.50.40.50.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, country:US, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value36424037441617202122202320
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.20.20.20.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.20.20.20.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other country:US jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, us-gaap:NonUs, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value214201219234217209234260271231248291283
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.91.01.31.01.01.11.31.41.11.21.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.91.01.31.01.01.11.31.41.11.21.41.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other us-gaap:NonUs jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Other, us-gaap:NonUs, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value59635764621615161517161714
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.30.30.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.30.30.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Other us-gaap:NonUs jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherImmunology, country:US, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value5.07.00.00.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherImmunology country:US jnj:Pharmaceutical jnj:Immunology100.0100.00.00.00.00.00.00.00.00.00.00.0

jnj:OtherImmunology, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value1.02.03.03.03.02.02.03.03.03.02.03.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherImmunology us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherInfectiousDiseases, country:US, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value16212425293233313034353646
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.10.10.10.20.20.20.10.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.10.10.10.20.20.20.10.20.20.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherInfectiousDiseases country:US jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherInfectiousDiseases, us-gaap:NonUs, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value819678878767808682809611096
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.40.50.40.30.40.40.40.40.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.40.40.50.40.30.40.40.40.40.50.50.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherInfectiousDiseases us-gaap:NonUs jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherOncology, country:US, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value232121202212291787671715135
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.10.10.10.60.40.40.40.30.30.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.10.10.10.10.60.40.40.40.30.30.20.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherOncology country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherOncology, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value971617687829795928793858599
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.70.40.50.40.50.50.40.40.50.40.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.70.40.50.40.50.50.40.40.50.40.40.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:OtherOncology us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA, country:US, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value368380379379396390373344315322297277273
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.71.82.11.91.91.81.71.61.61.51.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.61.71.82.11.91.91.81.71.61.61.51.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA country:US jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value137166147130184155135191208173193215205
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.70.70.90.70.70.91.00.80.91.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.60.70.70.70.90.70.70.91.00.80.91.01.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZA us-gaap:NonUs jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PROCRITEPREX, country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value5962697076118126113148151178156189
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.40.40.60.60.50.70.70.90.70.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.40.40.60.60.50.70.70.90.70.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PROCRITEPREX country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PROCRITEPREX, us-gaap:NonUs, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value69646366796572707870778087
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.40.40.30.30.30.40.30.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.40.40.30.30.30.40.30.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:PROCRITEPREX us-gaap:NonUs jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:RISPERDALCONSTA, country:US, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value72677074767779817777768082
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.40.40.40.40.40.40.40.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.30.30.30.40.40.40.40.40.40.40.40.40.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:RISPERDALCONSTA country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:RISPERDALCONSTA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value8489817994828910110210199108114
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.40.50.40.40.50.50.50.50.50.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.40.40.40.50.40.40.50.50.50.50.50.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:RISPERDALCONSTA us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Remicade, country:US, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value540489634593625755749801774843987918916
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.23.03.23.03.63.63.93.94.14.94.44.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.23.03.23.03.63.63.93.94.14.94.44.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Remicade country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Remicade, jnj:UNITEDSTATESExports, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value9357781331106888627690100104142
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.40.70.50.30.40.30.40.40.50.50.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.40.30.40.70.50.30.40.30.40.40.50.50.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Remicade jnj:UNITEDSTATESExports jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Remicade, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value255232209208256212299244252305292298331
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.01.01.11.21.01.41.21.31.51.41.41.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.01.01.11.21.01.41.21.31.51.41.41.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Remicade us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SPINEOTHER, country:US, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value433403449270423488472490465496473498463
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.91.82.11.52.02.42.32.42.32.42.32.42.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.91.82.11.52.02.42.32.42.32.42.32.42.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SPINEOTHER country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SPINEOTHER, us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value343303295230280329306328323335313347341
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.41.41.31.41.61.51.61.61.61.51.71.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.41.41.31.41.61.51.61.61.61.51.71.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SPINEOTHER us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SURGICAL, country:US, jnj:MedicalDevices, jnj:Vision


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value115101984593117120128125137133139131
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.20.40.60.60.60.60.70.70.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.20.40.60.60.60.60.70.70.70.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SURGICAL country:US jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SURGICAL, us-gaap:NonUs, jnj:MedicalDevices, jnj:Vision


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value19918715396160191180191180180164190177
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.80.70.50.80.90.90.90.90.90.80.90.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.90.80.70.50.80.90.90.90.90.90.80.90.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SURGICAL us-gaap:NonUs jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SimponiSimponiAria, country:US, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value290255312256272302313281263272281274224
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.11.51.41.31.51.51.41.31.31.41.31.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.11.51.41.31.51.51.41.31.31.41.31.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SimponiSimponiAria country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:SimponiSimponiAria, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value294307280289258213273282261210255274294
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.41.31.61.21.01.31.41.31.01.31.31.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.31.41.31.61.21.01.31.41.31.01.31.31.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:SimponiSimponiAria us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Stelara, country:US, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value149613311313113812171194121210588821009889919652
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.46.06.26.25.95.85.85.14.44.94.44.43.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.46.06.26.25.95.85.85.14.44.94.44.43.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Stelara country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Stelara, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value778817634558603506487499523435421422409
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.73.03.02.92.42.32.42.62.12.12.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.73.03.02.92.42.32.42.62.12.12.02.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Stelara us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:TRAUMA, country:US, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value447450433354407413415407417403395394407
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.92.02.11.92.02.02.02.02.12.01.91.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.92.02.11.92.02.02.02.02.12.01.91.92.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:TRAUMA country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:TRAUMA, us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value263282253198247273262265268271259281289
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.31.21.11.21.31.31.31.31.31.31.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.31.21.11.21.31.31.31.31.31.31.31.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:TRAUMA us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Tremfya, country:US, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value32527422224118719922117616814214310266
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.21.11.30.91.01.10.90.80.70.70.50.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.41.21.11.30.91.01.10.90.80.70.70.50.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Tremfya country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Tremfya, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value155143105101109716959493328246.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.60.50.60.50.30.30.30.20.20.10.10.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.70.60.50.60.50.30.30.30.20.20.10.10.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Tremfya us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:UPTRAVI, country:US, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value268259226254212178185175176165154155124
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.21.11.41.00.90.90.90.90.80.80.70.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.11.21.11.41.00.90.90.90.90.80.80.70.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:UPTRAVI country:US jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:UPTRAVI, us-gaap:NonUs, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value45463428383025282216171616
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.20.20.20.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.20.20.20.20.20.10.10.10.10.10.10.10.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:UPTRAVI us-gaap:NonUs jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:VELCADE, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value10598108115149224263252271280313
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.60.71.11.31.21.31.31.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.50.50.50.60.71.11.31.21.31.31.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:VELCADE us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Xarelto, country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value569589630559527609613549542608612679578
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.42.63.03.02.52.93.02.72.73.03.03.32.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.42.63.03.02.52.93.02.72.73.03.03.32.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Xarelto country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ZYTIGA, country:US, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value21505887139194233198185351527486407
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.20.30.50.70.91.11.00.91.72.62.32.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.10.20.30.50.70.91.11.00.91.72.62.32.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ZYTIGA country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ZYTIGA, us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value542588532480552483508500494435431423438
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.62.52.62.72.32.52.42.52.12.12.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.32.62.52.62.72.32.52.42.52.12.12.02.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:ZYTIGA us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments

jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value3735354335143296362535673469354433183536341535043398354033563478322834323261341931953320331434833390360635893744355737533611365836753652358136193595366837403793368236103567364737664249398938543711
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax16.015.916.718.017.517.216.717.216.617.316.816.817.017.517.118.518.219.018.318.518.318.619.419.619.519.819.419.219.620.420.520.521.020.821.022.022.322.623.422.922.823.123.823.824.125.726.525.324.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax16.015.916.718.017.517.216.717.216.617.316.816.817.017.517.118.518.219.018.318.518.318.619.419.619.519.819.419.219.620.420.520.521.020.821.022.022.322.623.422.922.823.123.823.824.125.726.525.324.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:MedicalDevices


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-30
Value697865796150428859326632638364896459666865876972676769746599672662936442615964096109609463586258657172427060
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.929.529.223.428.732.030.831.632.332.732.433.533.834.533.635.735.435.634.634.734.935.635.736.035.637.139.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.929.529.223.428.732.030.831.632.332.732.433.533.834.533.635.735.435.634.634.734.935.635.736.035.637.139.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value1259912199114181075211134105481087710529102441019010346103549844968196958635824582328400865481788064769479467726799983078509749872967036702567686525640262916133609459826233605957105495555356385993524954985780
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax54.054.754.258.653.850.852.551.251.250.050.849.749.247.949.345.846.445.547.146.846.845.345.044.744.543.845.043.641.439.740.039.338.737.237.538.238.037.537.437.637.536.536.736.236.136.234.836.138.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax54.054.754.258.653.850.852.551.251.250.050.849.749.247.949.345.846.445.547.146.846.845.345.044.744.543.845.043.641.439.740.039.338.737.237.538.238.037.537.437.637.536.536.736.236.136.234.836.138.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementBusinessSegments, us-gaap:Subsegments

jnj:MedicalDevices, jnj:InterventionalSolutions


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value1046949836590727774741750732686653667640621553573549
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.54.34.03.23.53.73.63.63.73.43.23.23.23.12.83.03.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.54.34.03.23.53.73.63.63.73.43.23.23.23.12.83.03.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices jnj:InterventionalSolutions100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value22272113208314512038227321382224220422622111226222502286220422932275
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.69.59.97.99.811.010.310.811.011.110.410.911.211.311.212.212.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9.69.59.97.99.811.010.310.811.011.110.410.911.211.311.212.212.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:MedicalDevices, jnj:Surgery


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value25222372215215512100244223112353239525872376251524232558234623842271
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax10.810.610.28.510.111.811.111.412.012.711.712.112.112.711.912.712.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax10.810.610.28.510.111.811.111.412.012.711.712.112.112.711.912.712.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:MedicalDevices, jnj:Vision


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-02
Value118311451081695106711411193116111291133113211731115111910911055
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.15.15.13.85.25.55.85.65.65.65.65.65.65.55.65.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.15.15.13.85.25.55.85.65.65.65.65.65.65.55.65.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value11261127128111841160125613161275134513901391151815171622158516051475
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.85.06.16.55.66.16.36.26.76.86.87.37.68.08.18.58.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.85.06.16.55.66.16.36.26.76.86.87.37.68.08.18.58.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value42313914378935233638352237113466325133423398333830423086326929592930
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.117.518.019.217.617.017.916.916.216.416.716.015.215.316.615.716.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.117.518.019.217.617.017.916.916.216.416.716.015.215.316.615.716.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value10281007864878920866839862846802823849830800813792749
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.44.54.14.84.44.24.04.24.23.94.04.14.14.04.14.24.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.44.54.14.84.44.24.04.24.23.94.04.14.14.04.14.24.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value18081721160515871658156615951538162915001490152815591524149814671497
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.87.77.68.78.07.57.77.58.17.47.37.37.87.57.67.88.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.87.77.68.78.07.57.77.58.17.47.37.37.87.57.67.88.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value35353570312927913013271627612697251824892588245623112039189817271594
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.216.014.815.214.613.113.313.112.612.212.711.811.510.19.79.29.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.216.014.815.214.613.113.313.112.612.212.711.811.510.19.79.29.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-02
Value870861749789745623654690656667656665585610632850.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.73.93.64.33.63.03.23.43.33.33.23.22.93.03.20.50.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.73.93.64.33.63.03.23.43.33.33.23.22.93.03.20.50.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical

country:US


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-03
Value1191911111110869539106991077410791104031012910629106641064099511046910290972693789537938195729321879189118692860488429132820480147925794680257460779173607219698568687447760872297131
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax51.149.852.652.051.751.952.150.650.652.152.451.149.751.852.451.652.852.752.651.853.351.450.150.047.147.946.845.343.745.144.445.842.545.744.744.743.042.944.947.046.247.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax51.149.852.652.051.751.952.150.650.652.152.451.149.751.852.451.652.852.752.651.853.351.450.150.047.147.946.845.343.745.144.445.842.545.744.744.743.042.944.947.046.247.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:AsiaPacificAfrica


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-01
Value4358437238813601366339893971378037183840369434833382307632113278298330463224300333083359344433313482333033543216355434543222
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.719.618.419.617.719.219.318.918.318.418.517.718.017.318.017.717.117.818.117.318.118.217.718.419.018.918.818.420.220.319.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax18.719.618.419.617.719.219.318.918.318.418.517.718.017.318.017.717.117.818.117.318.118.217.718.419.018.918.818.420.220.319.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:AsiaPacificAfrica100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:WesternHemisphereExcludingUS


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-01
Value1367142412961133150214881455150315501540156715691499145413961542133114631501163917821820186316951891184219051783194118241728
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.96.46.16.27.37.27.17.57.67.47.88.08.08.27.88.37.68.68.49.49.89.99.69.410.310.510.710.211.110.710.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.96.46.16.27.37.27.17.57.67.47.88.08.08.27.88.37.68.68.49.49.89.99.69.410.310.510.710.211.110.710.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax jnj:WesternHemisphereExcludingUS100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

srt:Europe


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-01
Value56685414481940634827446147334609441648104797
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax24.324.322.922.223.321.523.023.021.723.124.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax24.324.322.922.223.321.523.023.021.723.124.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax srt:Europe100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-02
Value113931121099968797999299739938101599892976596841019010058972693609113838885698439
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax48.950.247.448.048.348.147.949.449.447.947.648.950.348.247.648.447.247.347.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax48.950.247.448.048.348.147.949.449.447.947.648.950.348.247.648.447.247.347.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments

country:US, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value1751161115561557174014701394153714381479137014761436
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.57.27.48.58.47.16.77.57.27.36.77.17.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.57.27.48.58.47.16.77.57.27.36.77.17.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:MedicalDevices


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value3299305430921862289831353057308331093214319732653161
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.213.714.710.214.015.114.715.015.515.815.715.715.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.213.714.710.214.015.114.715.015.515.815.715.715.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value6869644664386120606161696340578355825936609758995354
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.528.930.533.429.329.730.628.127.929.130.028.326.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.528.930.533.429.329.730.628.127.929.130.028.326.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Consumer


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value1984193219581739188520972075200718802057204520281962
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.58.79.39.59.110.110.09.89.410.110.19.79.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.58.79.39.59.110.110.09.89.410.110.19.79.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Consumer100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value3679352530582426303434973326340633503454339037073606
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.815.814.513.214.716.916.016.616.716.916.717.818.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.815.814.513.214.716.916.016.616.716.916.717.818.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value5730575349804632507343794537474646624254424944554490
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax24.625.823.625.324.521.121.923.123.320.920.921.422.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax24.625.823.625.324.521.121.923.123.320.920.921.422.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments, us-gaap:Subsegments

country:US, jnj:MedicalDevices, jnj:InterventionalSolutions


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value475434399255365377357366343336320323304
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.01.91.91.41.81.81.71.81.71.61.61.61.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.01.91.91.41.81.81.71.81.71.61.61.61.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices jnj:InterventionalSolutions100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value132312491308869125013691301133113181358128413321307
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.75.66.24.76.06.66.36.56.66.76.36.46.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax5.75.66.24.76.06.66.36.56.66.76.36.46.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:MedicalDevices, jnj:Surgery


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value10358989134908449619409261001109410161022993
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.44.04.32.74.14.64.54.55.05.45.04.95.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.44.04.32.74.14.64.54.55.05.45.04.95.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:MedicalDevices, jnj:Vision


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value467472473248439428459461446426452459440
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.02.12.21.42.12.12.22.22.22.12.22.22.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.02.12.21.42.12.12.22.22.22.12.22.22.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value7807999318378069309559029471049102611011103
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.64.44.63.94.54.64.44.75.15.05.35.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.33.64.44.63.94.54.64.44.75.15.05.35.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value2748241325582362241025172582237921632356240023172000
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax11.810.812.112.911.612.112.511.610.811.611.811.110.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax11.810.812.112.911.612.112.511.610.811.611.811.110.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value444512413416436435418387357372345328333
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.92.32.02.32.12.12.01.91.81.81.71.61.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.92.32.02.32.12.12.01.91.81.81.71.61.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value842771759778748747785664723660651639624
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.63.53.64.23.63.63.83.23.63.23.23.13.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.63.53.64.23.63.63.83.23.63.23.23.13.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value14621377126711811175115311711013962106312501085933
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.36.26.06.45.75.65.64.94.85.26.15.24.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.36.26.06.45.75.65.64.94.85.26.15.24.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value595573510545486388427439430436425429361
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.62.62.43.02.31.92.12.12.12.12.12.11.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.62.62.43.02.31.92.12.12.12.12.12.11.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax country:US jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices, jnj:InterventionalSolutions


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value572514437335362398382385389350333344336
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.32.11.81.71.91.81.91.91.71.61.71.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.32.11.81.71.91.81.91.91.71.61.71.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices jnj:InterventionalSolutions100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices, jnj:Orthopaedics


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value904864774583788904837894885904827930943
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.93.93.73.23.84.44.04.34.44.44.14.54.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.93.93.73.23.84.44.04.34.44.44.14.54.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices jnj:Orthopaedics100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices, jnj:Surgery


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value1487147412391060125714811371142713941493136014931430
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.46.65.95.86.17.16.66.97.07.36.77.27.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.46.65.95.86.17.16.66.97.07.36.77.27.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices jnj:Surgery100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:MedicalDevices, jnj:Vision


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value716673608447628713734701682707680714675
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.13.02.92.43.03.43.53.43.43.53.33.43.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.13.02.92.43.03.43.53.43.43.53.33.43.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:MedicalDevices jnj:Vision100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:CardiovascularMetabolismOther


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value346328351347354327360373398341365417414
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.51.71.91.71.61.71.82.01.71.82.02.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.51.51.71.91.71.61.71.82.01.71.82.02.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:CardiovascularMetabolismOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:Immunology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value14831501123011611228100511291087108898699810211042
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.46.75.86.35.94.85.45.35.44.84.94.95.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax6.46.75.86.35.94.85.45.35.44.84.94.95.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:Immunology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:InfectiousDiseases


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value585494451463483430421475489430478521497
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.22.12.52.32.12.02.32.42.12.32.52.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.52.22.12.52.32.12.02.32.42.12.32.52.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:InfectiousDiseases100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:Neuroscience


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value967949846809910819810875905840839889935
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.14.34.04.44.43.93.94.34.54.14.14.34.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.14.34.04.44.43.93.94.34.54.14.14.34.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:Neuroscience100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:Oncology


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value2073219318621609183915631590168415561426133813711378
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.99.88.88.88.97.57.78.27.87.06.66.66.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.99.88.88.88.97.57.78.27.87.06.66.66.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:Oncology100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:NonUs, jnj:Pharmaceutical, jnj:PulmonaryHypertension


Revenue
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value275288239243260235227251226231231236224
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.31.11.31.31.11.11.21.11.11.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.21.31.11.31.31.11.11.21.11.11.11.11.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:NonUs jnj:Pharmaceutical jnj:PulmonaryHypertension100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Revenues

us-gaap:Revenues

us-gaap:Revenues


Revenues
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value23312223212108218336206912074720729205622002120394203482083020009201951965018839177661810617820184821748217811171021778717374182541846719495181151835517575178771750517558170521647516139162551600516597161731564414982153301563116551150811523915026
Percentage of Revenues100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Selling General And Administrative Expense

us-gaap:SellingGeneralAndAdministrativeExpense

us-gaap:SellingGeneralAndAdministrativeExpense


Selling
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value60735432543149935203603953745546521959915543574352636025539652624737530947725176468850815384484758225468548151835917531453765223566152284965501554585240521550565180470947564779
Percentage of SellingGeneralAndAdministrativeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax26.124.325.827.225.129.125.927.026.129.427.227.626.329.827.527.926.729.326.828.026.829.730.327.931.929.628.128.632.230.230.129.832.230.730.131.133.632.731.431.333.131.431.030.6

Assets

us-gaap:Assets

us-gaap:Assets


Assets
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value1764401725571748941706931583801550171577281555211551171500271529541557031553651566251573031556581528071449181412081403691398141362311334111332661320361285901311191320971352001333301326831269331243251215361213471189511157501161941136441118211121141081501029089468284912
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Assets us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:CorporateNonSegment, jnj:GeneralCorporate


Assetsus-gaap:
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-28
Value31803253562418727410499874551641297
Percentage of Assets18.216.115.817.435.434.131.5
Percentage of Assets18.216.115.817.435.434.131.5
Percentage of Assets us-gaap:CorporateNonSegment jnj:GeneralCorporate100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, jnj:Consumer


Assetsus-gaap:
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-28
Value27355266182587725030239712077221813
Percentage of Assets15.616.916.915.917.015.616.6
Percentage of Assets15.616.916.915.917.015.616.6
Percentage of Assets us-gaap:OperatingSegments jnj:Consumer100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, jnj:MedicalDevices


Assetsus-gaap:
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-28
Value49578494624625445413397734097941445
Percentage of Assets28.331.430.228.928.230.731.6
Percentage of Assets28.331.430.228.928.230.731.6
Percentage of Assets us-gaap:OperatingSegments jnj:MedicalDevices100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, jnj:Pharmaceutical


Assetsus-gaap:
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-28
Value66158562925663659450274772614425803
Percentage of Assets37.835.737.037.819.519.619.7
Percentage of Assets37.835.737.037.819.519.619.7
Percentage of Assets us-gaap:OperatingSegments jnj:Pharmaceutical100.0100.0100.0100.0100.0100.0100.0

us-gaap:Assets us-gaap:StatementBusinessSegments

jnj:SegmentsTotal


Assetsus-gaap:
Period End2021-01-032019-12-29
Value143091132372
Percentage of Assets81.883.9
Percentage of Assets81.883.9
Percentage of Assets jnj:SegmentsTotal100.0100.0

Liabilities

us-gaap:Liabilities

us-gaap:Liabilities


Liabilities
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value10686010672311161610622095402937239825797311943329107293202910779247693370971438167980885745777079067600673416358462261617126090560712613675550657152567485863057129546605468156521551905531654828565645029449982482874632944094
Percentage of Liabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets60.661.863.862.260.260.562.362.660.860.760.958.559.559.661.852.552.951.550.148.248.246.746.746.346.147.246.842.042.342.644.245.044.045.046.646.447.847.249.845.044.644.645.046.6

Liabilities And Stockholders Equity

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:LiabilitiesAndStockholdersEquity


Liabilities
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value17644017255717489417069315838015501715772815552115511715002715295415570315536515662515730315565815280714491814120814036913981413623113341113326613203612859013111913209713520013333013268312693312432512153612134711895111575011619411364411182111211410815010290894682
Percentage of LiabilitiesAndStockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Assets Current

us-gaap:AssetsCurrent

us-gaap:AssetsCurrent


Assets
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value5376952533512375757845892442264527444333417994198746033471944543842768430884182938789633476503263319662916273860210634946100158192593115997360119573695640752176512734722846116447914161557007543165344352673492214730739541
Percentage of AssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets30.530.429.333.729.028.528.728.526.928.030.130.329.227.327.426.925.443.746.145.147.446.145.147.646.245.345.245.444.543.042.541.141.238.938.037.736.049.147.847.847.045.546.041.8

Cash And Cash Equivalents At Carrying Value

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashAndCashEquivalentsAtCarryingValue


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032008-12-282007-12-30
Value1433212671139851896511174155301730516249143761473418107160561756914639178241572112598209091897218205186401386113732136391063911988145231381814236197222092717204173071485514911154861404230267245421561714974223561935514338127131374315810107687770
Percentage of CashAndCashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets8.17.38.011.17.110.011.010.49.39.811.810.311.39.311.310.18.214.413.413.013.310.210.310.28.19.311.110.510.514.815.813.613.912.212.313.012.126.021.614.013.420.718.80.00.00.016.712.70.0

us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:AvailableforsaleSecurities


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value391542944755349434944275311032091865417181547847
Percentage of CashAndCashEquivalentsAtCarryingValue27.333.934.018.431.327.518.019.713.028.345.048.9
Percentage of Assets2.22.52.72.02.22.82.02.11.22.85.35.0
Percentage of Assets us-gaap:AvailableforsaleSecurities0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value1041783779230154717680112551419513040125111056399538209
Percentage of CashAndCashEquivalentsAtCarryingValue72.766.166.081.668.772.582.080.387.071.755.051.1
Percentage of Assets5.94.95.39.14.87.39.08.48.17.06.55.3
Percentage of Assets us-gaap:HeldtomaturitySecurities0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:CashAndCashEquivalentsAtCarryingValue us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableforsaleSecurities, us-gaap:CorporateDebtSecurities


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value2525241114151514202810.012
Percentage of CashAndCashEquivalentsAtCarryingValue0.20.20.20.10.10.10.10.10.10.20.10.1
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:AvailableforsaleSecurities us-gaap:CorporateDebtSecurities0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AvailableforsaleSecurities, us-gaap:SovereignDebtSecurities


Cash
Period End2021-04-042019-09-292019-06-302019-03-312018-09-30
Value1.00.00.00.00.0
Percentage of CashAndCashEquivalentsAtCarryingValue0.00.00.00.00.0
Percentage of Assets0.00.00.00.00.0
Percentage of Assets us-gaap:AvailableforsaleSecurities us-gaap:SovereignDebtSecurities0.00.00.00.00.0

us-gaap:AvailableforsaleSecurities, us-gaap:USTreasuryAndGovernment


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value389042684731348334804260309531951845414381447835
Percentage of CashAndCashEquivalentsAtCarryingValue27.133.733.818.431.127.417.919.712.828.145.048.8
Percentage of Assets2.22.52.72.02.22.72.02.11.22.85.35.0
Percentage of Assets us-gaap:AvailableforsaleSecurities us-gaap:USTreasuryAndGovernment0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, jnj:OtherReverseRepurchaseAgreements


Cash
Period End2020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value430460473375241219350443479
Percentage of CashAndCashEquivalentsAtCarryingValue2.34.13.02.21.51.52.42.43.0
Percentage of Assets0.30.30.30.20.20.10.20.30.3
Percentage of Assets us-gaap:HeldtomaturitySecurities jnj:OtherReverseRepurchaseAgreements0.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:BankTimeDeposits


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value1129947877660579765906691651533485932
Percentage of CashAndCashEquivalentsAtCarryingValue7.97.56.33.55.24.95.24.34.53.62.75.8
Percentage of Assets0.60.50.50.40.40.50.60.40.40.40.30.6
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:BankTimeDeposits0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:Cash


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value231322472863223122152499263726672615277826192575
Percentage of CashAndCashEquivalentsAtCarryingValue16.117.720.511.819.816.115.216.418.218.914.516.0
Percentage of Assets1.31.31.61.31.41.61.71.71.71.91.71.7
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:Cash0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:CorporateDebtSecurities


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-09-30
Value21911890145157130110398891159264449200
Percentage of CashAndCashEquivalentsAtCarryingValue15.314.910.43.02.76.75.17.11.83.01.2
Percentage of Assets1.21.10.80.30.20.70.60.70.20.30.1
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:CorporateDebtSecurities0.00.00.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:MoneyMarketFunds


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value261820942102848515282424286414811368419533971763
Percentage of CashAndCashEquivalentsAtCarryingValue18.316.515.044.713.715.616.69.19.528.518.811.0
Percentage of Assets1.51.21.25.01.01.61.81.00.92.82.21.1
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:MoneyMarketFunds0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:RepurchaseAgreements


Cash
Period End2021-01-032019-12-292018-12-30
Value193763753009
Percentage of CashAndCashEquivalentsAtCarryingValue13.936.816.6
Percentage of Assets1.14.02.0
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:RepurchaseAgreements0.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchase


Cash
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-30
Value209111993094237239656182701420682260
Percentage of CashAndCashEquivalentsAtCarryingValue14.69.516.321.225.538.048.814.014.1
Percentage of Assets1.20.71.81.52.64.04.51.41.5
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchase0.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:SovereignDebtSecurities


Cash
Period End2021-07-042020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-09-30
Value75225901496193801900.0
Percentage of CashAndCashEquivalentsAtCarryingValue0.52.00.60.93.82.61.30.0
Percentage of Assets0.00.10.10.10.40.20.10.0
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:SovereignDebtSecurities0.00.00.00.00.00.00.00.0

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents


Cash
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302017-12-312017-01-01
Value1433212671139851896511174155301730516249143761473418107160561782418972
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets8.17.38.011.17.110.011.010.49.39.811.810.311.313.4

Marketable Securities Current

us-gaap:MarketableSecuritiesCurrent

us-gaap:MarketableSecuritiesCurrent


Marketable
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-28
Value1097411948112001181679612494198216969026021580330857056547251025518434229352222823944259942464423667233151933118566
Percentage of MarketableSecuritiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets6.26.96.46.95.01.61.31.10.60.41.02.10.40.40.30.30.212.716.215.817.119.118.517.817.715.014.2

us-gaap:MarketableSecuritiesCurrent us-gaap:InformationByCategoryOfDebtSecurity

us-gaap:AvailableforsaleSecurities


Marketable
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value91411019992879897655313981258111890250215803308
Percentage of MarketableSecuritiesCurrent83.385.482.983.882.356.163.565.9100.083.4100.0100.0
Percentage of Assets5.25.95.35.84.10.90.80.70.60.31.02.1
Percentage of Assets us-gaap:AvailableforsaleSecurities0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities


Marketable
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value1833174919131919140810967245780.01000.00.0
Percentage of MarketableSecuritiesCurrent16.714.617.116.217.743.936.534.10.016.60.00.0
Percentage of Assets1.01.01.11.10.90.70.50.40.00.10.00.0
Percentage of Assets us-gaap:HeldtomaturitySecurities0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:MarketableSecuritiesCurrent us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType

us-gaap:AvailableforsaleSecurities, jnj:OtherSovereignSecurities


Marketable
Period End2021-01-03
Value14
Percentage of MarketableSecuritiesCurrent0.1
Percentage of Assets0.0
Percentage of Assets us-gaap:AvailableforsaleSecurities jnj:OtherSovereignSecurities0.0

us-gaap:AvailableforsaleSecurities, us-gaap:CorporateDebtSecurities


Marketable
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value232231226236242236251258245233250259
Percentage of MarketableSecuritiesCurrent2.11.92.02.03.09.512.715.227.238.715.87.8
Percentage of Assets0.10.10.10.10.20.20.20.20.20.20.20.2
Percentage of Assets us-gaap:AvailableforsaleSecurities us-gaap:CorporateDebtSecurities0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AvailableforsaleSecurities, us-gaap:SovereignDebtSecurities


Marketable
Period End2021-07-042021-04-042020-09-272019-09-292019-06-302019-03-312018-09-30
Value1.07.010.04.00.00.00.0
Percentage of MarketableSecuritiesCurrent0.00.10.10.20.00.00.0
Percentage of Assets0.00.00.00.00.00.00.0
Percentage of Assets us-gaap:AvailableforsaleSecurities us-gaap:SovereignDebtSecurities0.00.00.00.00.00.00.0

us-gaap:AvailableforsaleSecurities, us-gaap:USTreasuryAndGovernment


Marketable
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-30
Value890899619047965163061162100785665726913303049
Percentage of MarketableSecuritiesCurrent81.283.480.881.779.246.650.850.572.844.784.292.2
Percentage of Assets5.05.85.25.74.00.70.60.60.40.20.92.0
Percentage of Assets us-gaap:AvailableforsaleSecurities us-gaap:USTreasuryAndGovernment0.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:CorporateDebtSecurities


Marketable
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-03-312018-09-30
Value103913491223127297810964344881000.0
Percentage of MarketableSecuritiesCurrent9.511.310.910.812.343.921.928.816.60.0
Percentage of Assets0.60.80.70.70.60.70.30.30.10.0
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:CorporateDebtSecurities0.00.00.00.00.00.00.00.00.00.0

us-gaap:HeldtomaturitySecurities, us-gaap:SovereignDebtSecurities


Marketable
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-29
Value7944006906474300.029090
Percentage of MarketableSecuritiesCurrent7.23.36.25.55.40.014.65.3
Percentage of Assets0.50.20.40.40.30.00.20.1
Percentage of Assets us-gaap:HeldtomaturitySecurities us-gaap:SovereignDebtSecurities0.00.00.00.00.00.00.00.0

Accounts Receivable Net Current

us-gaap:AccountsReceivableNetCurrent

us-gaap:AccountsReceivableNetCurrent


Accounts
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value14871149381357614579146451487414481148011465314115140981404814111141661349013155132831230011699117981206211406107341136611968115331098511615122571211611713120271161411515113091117510992109821058110552109821086197749646
Percentage of AccountsReceivableNetCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets8.48.77.88.59.29.69.29.59.49.49.29.09.19.08.68.58.78.58.38.48.68.48.08.59.19.08.48.89.19.18.89.59.39.59.39.49.59.59.39.49.810.09.510.2

Inventory Net

us-gaap:InventoryNet

us-gaap:InventoryNet


Inventory
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value101009952934495999424886890209173926390868599867888109014876595219699887881448488852381708053820682988085818484198155800978788124782276917495780976976800628564286413620053785180
Percentage of InventoryNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets5.75.85.35.66.05.75.75.96.06.15.65.65.75.85.66.16.36.15.86.06.16.06.06.26.36.36.26.46.06.05.96.46.36.36.26.66.65.95.55.75.75.75.25.5

Prepaid Expense And Other Assets Current

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:PrepaidExpenseAndOtherAssetsCurrent


Prepaid
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-02
Value349230243132252825882358239222202411259926992896256926412537292229542826328226003122330730473010305837313486310739823932400333123425326030842789289426832633305632902273
Percentage of PrepaidExpenseAndOtherAssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.01.81.81.51.61.51.51.41.61.71.81.91.71.71.61.91.92.02.31.92.22.42.32.32.32.92.72.42.92.93.02.62.82.72.52.32.52.32.32.72.92.2

Land

us-gaap:Land

us-gaap:Land


Land
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-03
Value882854807829753780833885793754738714
Percentage of Land100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.50.50.50.50.50.60.60.70.70.70.70.8

Machinery And Equipment Gross

us-gaap:MachineryAndEquipmentGross

us-gaap:MachineryAndEquipmentGross


Machinery
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-03
Value291042696425992259492355422511222062252721075191821803217153
Percentage of MachineryAndEquipmentGross100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets16.617.117.016.516.716.916.917.017.416.917.518.1

Noncurrent Assets

us-gaap:NoncurrentAssets us-gaap:ConsolidationItems

us-gaap:NoncurrentAssets

us-gaap:OperatingSegments


Noncurrent
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-28
Value1075329789194035100996644036215064042
Percentage of NoncurrentAssets100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets61.562.161.564.245.646.648.8
Percentage of Assets us-gaap:OperatingSegments0.00.00.00.00.00.00.0

us-gaap:NoncurrentAssets us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:CorporateNonSegment, jnj:GeneralCorporate


Noncurrent
Period End2021-01-032019-12-292018-12-302017-12-31
Value1029104910641143
Percentage of NoncurrentAssets1.01.11.11.1
Percentage of Assets0.60.70.70.7
Percentage of Assets us-gaap:CorporateNonSegment jnj:GeneralCorporate3.24.14.44.2

us-gaap:NoncurrentAssets us-gaap:ConsolidationItems, us-gaap:StatementGeographical

us-gaap:OperatingSegments, country:US


Noncurrent
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-28
Value49951415283711738556369343660936835
Percentage of NoncurrentAssets46.542.439.538.257.358.957.5
Percentage of Assets28.626.324.324.526.227.428.1
Percentage of Assets us-gaap:OperatingSegments country:US0.00.00.00.00.00.00.0

us-gaap:OperatingSegments, jnj:AsiaPacificAfrica


Noncurrent
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-28
Value5484548627332773251224932438
Percentage of NoncurrentAssets5.15.62.92.73.94.03.8
Percentage of Assets3.13.51.81.81.81.91.9
Percentage of Assets us-gaap:OperatingSegments jnj:AsiaPacificAfrica0.00.00.00.00.00.00.0

us-gaap:OperatingSegments, jnj:WesternHemisphereExcludingUS


Noncurrent
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-28
Value2734286227522990296128813210
Percentage of NoncurrentAssets2.52.92.93.04.64.65.0
Percentage of Assets1.61.81.81.92.12.22.4
Percentage of Assets us-gaap:OperatingSegments jnj:WesternHemisphereExcludingUS0.00.00.00.00.00.00.0

us-gaap:OperatingSegments, srt:Europe


Noncurrent
Period End2021-01-032019-12-292018-12-30
Value493634801551433
Percentage of NoncurrentAssets45.949.054.7
Percentage of Assets28.230.433.6
Percentage of Assets us-gaap:OperatingSegments srt:Europe0.00.00.0

us-gaap:NoncurrentAssets us-gaap:PropertyPlantAndEquipmentByType

us-gaap:OtherIntangibleAssets


Noncurrent
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-30
Value897958128278064851344968147393490545074551176
Percentage of NoncurrentAssets83.583.083.084.377.176.376.60.00.0
Percentage of Assets51.351.551.054.135.235.537.438.242.2
Percentage of Assets us-gaap:OtherIntangibleAssets0.00.00.00.00.00.00.00.00.0

us-gaap:PropertyPlantAndEquipment


Noncurrent
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-30
Value187661765817035170051591215905161261671016097
Percentage of NoncurrentAssets17.518.018.116.824.725.625.20.00.0
Percentage of Assets10.711.211.110.811.311.912.312.613.3
Percentage of Assets us-gaap:PropertyPlantAndEquipment0.00.00.00.00.00.00.00.00.0

Property Plant And Equipment Gross

us-gaap:PropertyPlantAndEquipmentGross

us-gaap:PropertyPlantAndEquipmentGross


Property
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value4720146430468044516244056432474333242625429054226241851415204129341996414664092840075386963777338373377793743036648363973611235403366853644836947362483713336432354013469534654340823329732550318293173632435318053042629251
Percentage of PropertyPlantAndEquipmentGross100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets26.826.926.826.527.827.927.527.427.728.227.426.726.626.826.426.326.226.726.727.327.027.527.527.327.427.528.027.627.327.228.028.728.528.528.628.728.828.028.028.428.929.429.630.9

Construction In Progress Gross

us-gaap:ConstructionInProgressGross

us-gaap:ConstructionInProgressGross


Construction
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-03
Value431636373876344833543528360032982740250425772521
Percentage of ConstructionInProgressGross100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.52.32.52.22.42.62.72.52.32.22.52.7

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment


Accumulated
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value2856928063280382730726458258462567425577256572526224816248912466124956244612430023617225052186122278218072146620743208462052920039205592064420792202522042320305196071897418557182371767517726170901710117461167211587314492
Percentage of AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets16.216.316.016.016.716.716.316.416.516.816.216.015.915.915.615.615.515.515.515.915.615.815.515.615.515.615.715.615.415.215.416.015.815.615.315.315.315.315.015.315.615.515.415.3

Amortization Of Intangible Assets

us-gaap:AmortizationOfIntangibleAssets

us-gaap:AmortizationOfIntangibleAssets


Amortization
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-01
Value120012001200110011001200110011001100110011001100110011141077480329305319294282293307312365335347351383327318335280378283205
Percentage of AmortizationOfIntangibleAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Property Plant And Equipment Net

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:PropertyPlantAndEquipmentNet


Property
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value186321836718766178551759817401176581704817248170001703516629166321704017005166281645816191159121609515972159641590515551155831536416126158041615515996167101612715794157211609715845156221482414739146351497415084145531475914365
Percentage of PropertyPlantAndEquipmentNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets10.610.610.710.511.111.211.211.011.111.311.110.710.710.910.810.710.811.211.311.511.411.711.911.711.811.912.312.011.912.012.612.712.712.913.313.313.512.813.013.113.413.914.115.616.9

Goodwill

us-gaap:Goodwill

us-gaap:Goodwill


Goodwill
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value358193568836393343073389033471336393329133661314503045330702303463114931906313083123424844228052317122104218482162921279214932134521832216362198922178227982285222337223492242421777214121633916138160491624316126152941486213719
Percentage of Goodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets20.320.720.820.121.421.621.321.421.721.019.919.719.519.920.320.120.417.116.116.515.816.016.216.016.316.616.716.416.316.617.218.018.018.418.518.318.514.114.214.414.514.914.915.716.2

us-gaap:Goodwill us-gaap:BusinessAcquisition

jnj:Momenta


Goodwillus-gaap:
Period End2020-10-01
Value1200
Percentage of Goodwill0.0
Percentage of Assets0.0
Percentage of Assets jnj:Momenta0.0

jnj:VerbSurgicalInc


Goodwillus-gaap:
Period End2021-01-03
Value200
Percentage of Goodwill0.5
Percentage of Assets0.1
Percentage of Assets jnj:VerbSurgicalInc0.0

us-gaap:Goodwill us-gaap:StatementBusinessSegments

jnj:Consumer


Goodwillus-gaap:
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-022010-01-03
Value1008710026103369907974695139736959598179730867087408578889988758848863083448263857575157412724072087406727476757984832485128531861784118477851984598179847082988335846481448074
Percentage of Goodwill28.228.128.428.928.828.428.928.829.230.928.528.528.328.627.828.327.633.636.237.034.033.933.533.934.534.135.236.937.938.437.437.737.737.938.038.838.251.851.451.952.153.254.3
Percentage of Assets5.75.85.95.86.26.16.26.26.36.55.75.65.55.75.65.75.65.85.96.15.45.45.45.45.65.75.96.06.26.46.46.86.87.07.07.17.17.37.37.57.57.98.5
Percentage of Assets jnj:Consumer0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.035.20.00.00.036.00.00.00.035.30.00.00.034.30.00.034.332.7

jnj:MedicalDevices


Goodwillus-gaap:
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-28
Value149271491515048149501492914884147341471914740127321272012850127261299413922137741371413646117021170211699115241150011454114681145911531
Percentage of Goodwill41.741.841.343.644.144.543.844.243.840.541.841.941.941.743.644.043.954.951.350.552.952.753.253.853.453.752.8
Percentage of Assets8.58.68.68.89.49.69.39.59.58.58.38.38.28.38.98.89.09.48.38.38.48.58.68.68.78.98.8
Percentage of Assets jnj:MedicalDevices0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

jnj:Pharmaceutical


Goodwillus-gaap:
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-01-022010-01-03
Value1080510747110099450921590749169897791048988906391129042925691098686889028542840289428902912288926172619261226262092205920652068205417781762179217681742174217211768181512251244
Percentage of Goodwill30.230.130.327.527.227.127.327.027.028.629.829.729.829.728.527.728.511.512.512.513.113.313.412.312.212.212.09.79.49.39.19.08.07.98.08.18.110.710.711.011.28.08.4
Percentage of Assets6.16.26.35.55.85.95.85.85.96.05.95.95.85.95.85.65.82.02.02.12.12.12.22.02.02.02.01.61.51.51.61.61.41.41.51.51.51.51.51.61.61.21.3
Percentage of Assets jnj:Pharmaceutical0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.010.20.00.00.08.70.00.00.07.70.00.00.07.20.00.06.15.8

Indefinite Lived Intangible Assets Excluding Goodwill

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill


Indefinite
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value17841178491904412695127341262511569111651126283039190922810356105861128311678116891046910331104251047810582104431027510399103101010587468724876887749138834483858553847889507998788379018116917278917675
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets10.110.310.97.48.08.17.37.27.35.56.05.96.76.87.27.57.67.27.37.47.57.87.87.77.98.07.76.66.56.66.67.26.76.97.07.17.76.96.97.17.28.57.78.1

us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

jnj:PurchasedInProcessResearchAndDevelopment


Indefinite
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-01-02
Value10736107881184957005807579646474290432313912253222634043473420145854620351234433383339334103420319132223195284213211117113411551504843829905957159418801849213
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill60.260.462.244.945.645.940.238.438.416.824.524.132.932.837.239.339.533.533.332.532.432.232.731.131.031.028.115.112.812.913.216.510.19.910.611.317.823.523.52.7
Percentage of Assets6.16.36.83.33.73.72.92.82.80.91.51.42.22.22.72.93.02.42.42.42.42.52.62.42.42.52.21.00.80.90.91.20.70.70.70.81.41.61.60.2
Percentage of Assets jnj:PurchasedInProcessResearchAndDevelopment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:Trademarks


Indefinite
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value710570617195699569276829692268756939691269377002695271137082709370696957688870427085717270237084717771157263742576077634761976347501755676487521735661186034
Percentage of IndefiniteLivedIntangibleAssetsExcludingGoodwill39.839.637.855.154.454.159.861.661.683.275.575.967.167.262.860.760.566.566.767.567.667.867.368.969.069.071.984.987.287.186.883.589.990.189.488.782.276.576.5
Percentage of Assets4.04.14.14.14.44.44.44.44.54.64.54.54.54.54.54.64.64.84.95.05.15.35.35.35.45.55.55.65.65.75.76.06.06.26.36.36.45.35.3
Percentage of Assets us-gaap:Trademarks0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Intangible Assets Net Excluding Goodwill

us-gaap:IntangibleAssetsNetExcludingGoodwill

us-gaap:IntangibleAssetsNetExcludingGoodwill


Intangible
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value5024451110534024700647413473384764347846493324689847611486375005652365532285456954942294662687627642256942584025764259882701727025272222630427122276432794728467277042800928752287902919918157181381822518378186871671616323
Percentage of IntangibleAssetsNetExcludingGoodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets28.529.630.527.529.930.530.230.831.831.331.131.232.233.433.835.136.020.319.019.718.419.019.319.520.521.020.819.920.120.721.122.422.323.023.724.225.215.616.016.316.417.316.217.2

Finite Lived Intangible Assets Net

us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:FiniteLivedIntangibleAssetsNet

jnj:PatentsAndTrademarks


Finite
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value20806214992237222283224792235723480239562508225415254102640126556283862920429947302586085544557983659347235543611411141994374437746174899501851645231532654745557558250084971
Percentage of FiniteLivedIntangibleAssetsNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets11.812.512.813.114.214.414.915.416.216.916.617.017.118.118.619.219.84.23.94.12.62.52.72.73.13.33.33.33.43.73.84.14.24.44.54.74.84.34.4
Percentage of Assets jnj:PatentsAndTrademarks0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OtherIntangibleAssets


Finite
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-01
Value1159711762119861202812200123561259412725129881318013011130081314413393127411294412995129121110011419115571178611767121021250712516127431318113781139761415514165141291429814725147551466751515284
Percentage of FiniteLivedIntangibleAssetsNet55.754.753.654.054.355.353.653.151.851.951.249.349.547.243.643.242.9212.2203.9196.9315.9339.5331.1335.1304.2298.1291.3301.1298.5285.3282.1274.3270.1268.5269.0265.5262.8102.9106.3
Percentage of Assets6.66.86.97.07.78.08.08.28.48.88.58.48.58.68.18.38.58.97.98.18.38.78.89.19.59.79.710.010.210.510.711.211.411.812.112.412.74.44.6
Percentage of Assets us-gaap:OtherIntangibleAssets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Intangible Assets Net Including Goodwill

us-gaap:IntangibleAssetsNetIncludingGoodwill us-gaap:BusinessAcquisition, us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:IntangibleAssetsNetIncludingGoodwill

jnj:A2020Acquisitions, us-gaap:InProcessResearchAndDevelopment


Intangible
Period End2021-01-03
Value7500
Percentage of IntangibleAssetsNetIncludingGoodwill100.0
Percentage of Assets4.3
Percentage of Assets jnj:A2020Acquisitions us-gaap:InProcessResearchAndDevelopment0.0

Deferred Tax Assets Liabilities Net

us-gaap:DeferredTaxAssetsLiabilitiesNet

us-gaap:DeferredTaxAssetsLiabilitiesNet


Deferred
Period End2021-07-04
Value600
Percentage of DeferredTaxAssetsLiabilitiesNet100.0
Percentage of Assets0.3

Other Assets Noncurrent

us-gaap:OtherAssetsNoncurrent

us-gaap:OtherAssetsNoncurrent


Other
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value71726538656261315782504256955307543051594182446544214518497150215273469044354245397741634413380438553605323250336435645949492715247737233417352138913956377339054193370539423690
Percentage of OtherAssetsNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets4.13.83.83.63.73.33.63.43.53.42.72.92.82.93.23.23.53.23.13.02.83.13.32.92.92.82.53.84.84.83.72.12.03.12.83.03.43.43.33.53.73.43.83.9

us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

us-gaap:EquitySecurities, jnj:EquityInvestmentswithReadilyDeterminableValue


Other
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value167814521481114014888261148863963830511697697731
Percentage of OtherAssetsNoncurrent23.422.222.618.625.716.420.216.317.716.112.215.615.816.2
Percentage of Assets1.00.80.80.70.90.50.70.60.60.60.30.40.40.5
Percentage of Assets us-gaap:EquitySecurities jnj:EquityInvestmentswithReadilyDeterminableValue0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:EquitySecurities, jnj:EquityInvestmentswithoutReadilyDeterminableValue


Other
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value824764738742712694712699677698681639624573
Percentage of OtherAssetsNoncurrent11.511.711.212.112.313.812.513.212.513.516.314.314.112.7
Percentage of Assets0.50.40.40.40.40.40.50.40.40.50.40.40.40.4
Percentage of Assets us-gaap:EquitySecurities jnj:EquityInvestmentswithoutReadilyDeterminableValue0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Equity Securities Fv Ni

us-gaap:EquitySecuritiesFvNi

us-gaap:EquitySecuritiesFvNi


Equity
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value167814521481114014888261148863963830511
Percentage of EquitySecuritiesFvNi100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.00.80.80.70.90.50.70.60.60.60.3

us-gaap:EquitySecuritiesFvNi us-gaap:FairValueByFairValueHierarchyLevel

us-gaap:FairValueInputsLevel1


Equity
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value167814521481114014888261148863963830511
Percentage of EquitySecuritiesFvNi100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.00.80.80.70.90.50.70.60.60.60.3
Percentage of Assets us-gaap:FairValueInputsLevel10.00.00.00.00.00.00.00.00.00.00.0

Accounts Payable Current

us-gaap:AccountsPayableCurrent

us-gaap:AccountsPayableCurrent


Accounts
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value87048503950570446765741185447491691269237537700065166443731063906135608269185971606159656668592861406719763366036193611362666055568753725831534451455085572557305689570156235541
Percentage of AccountsPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets4.94.95.44.14.34.85.44.84.54.64.94.54.24.14.64.14.04.24.94.34.34.45.04.44.75.25.85.04.64.64.74.84.64.44.84.54.44.45.05.15.15.35.55.9

Accrued Income Taxes Current

us-gaap:AccruedIncomeTaxesCurrent

us-gaap:AccruedIncomeTaxesCurrent


Accrued
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value1200187713921666163219302266250517011025818109692815591854118375911339717986909687509319161243500153510558627701711956117810641502125991485413368081007578442
Percentage of AccruedIncomeTaxesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.71.10.81.01.01.21.41.61.10.70.50.70.61.01.20.80.50.80.70.60.50.70.60.70.71.00.41.20.80.60.61.30.81.00.91.31.10.80.81.20.70.90.60.5

Accrued Liabilities Current

us-gaap:AccruedLiabilitiesCurrent

us-gaap:AccruedLiabilitiesCurrent


Accrued
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value10485132231396896298940838497159004829779467601604463946535730458976076526256355283565049965411506253195575655361887178771076856921664669047299649865334369460841364405409341004625
Percentage of AccruedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets5.97.78.05.65.65.46.25.85.35.35.03.94.14.24.63.84.03.64.03.84.03.74.13.84.04.35.04.75.35.85.85.55.35.76.05.55.63.84.13.73.93.84.04.9

Debt Current

us-gaap:DebtCurrent

us-gaap:DebtCurrent


Debt
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value260012002800390047007000
Percentage of DebtCurrent100.0100.0100.0100.0100.0100.0
Percentage of Assets1.50.81.82.53.35.2

Liabilities Current

us-gaap:LiabilitiesCurrent

us-gaap:LiabilitiesCurrent


Liabilities
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value3872140932424933884736772336893596435162313532911131230274372748827081305373180628872251192628723230215362213427747252602451223836250852298224359238402567525835237672252424262239352384821198228112168620985240112307221731
Percentage of LiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets21.923.724.322.823.221.722.822.620.219.420.417.617.717.319.420.418.917.318.616.515.416.220.819.018.618.519.117.418.017.919.420.419.118.520.020.120.618.220.119.418.722.222.423.0

Long Term Debt Current

us-gaap:LongTermDebtCurrent us-gaap:FairValueByMeasurementBasis

us-gaap:LongTermDebtCurrent

us-gaap:CarryingReportedAmountFairValueDisclosure


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-30
Value1799110026361499170421047.017691512
Percentage of LongTermDebtCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.00.71.71.01.21.60.01.31.2
Percentage of Assets us-gaap:CarryingReportedAmountFairValueDisclosure0.00.00.00.00.00.00.00.00.0

Long Term Debt

us-gaap:LongTermDebt us-gaap:BusinessAcquisition, us-gaap:LongtermDebtType

us-gaap:LongTermDebt

jnj:Idorsia, us-gaap:ConvertibleDebt


Long
Period End2021-01-032019-12-292018-12-302017-06-16
Value445500500500
Percentage of LongTermDebt100.0100.0100.0100.0
Percentage of Assets0.30.30.30.0
Percentage of Assets jnj:Idorsia us-gaap:ConvertibleDebt0.00.00.00.0

us-gaap:LongTermDebt us-gaap:DebtInstrument

jnj:A0.250NotesDue2022


Long
Period End2021-01-032019-12-292018-12-30
Value122711081137
Percentage of LongTermDebt275.7221.6227.4
Percentage of Assets0.70.70.7
Percentage of Assets jnj:A0.250NotesDue20220.00.00.0

jnj:A0.650NotesDue2024


Long
Period End2021-01-032019-12-292018-12-30
Value919829851
Percentage of LongTermDebt206.5165.8170.2
Percentage of Assets0.50.50.6
Percentage of Assets jnj:A0.650NotesDue20240.00.00.0

jnj:A1.150NotesDue2028


Long
Period End2021-01-032019-12-292018-12-30
Value915825847
Percentage of LongTermDebt205.6165.0169.4
Percentage of Assets0.50.50.6
Percentage of Assets jnj:A1.150NotesDue20280.00.00.0

jnj:A1.650NotesDue2035


Long
Period End2021-01-032019-12-292018-12-30
Value182716491693
Percentage of LongTermDebt410.6329.8338.6
Percentage of Assets1.01.01.1
Percentage of Assets jnj:A1.650NotesDue20350.00.00.0

jnj:A1.65Notesdue2021


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value9999999989989970.0
Percentage of LongTermDebt224.5199.8199.60.00.00.0
Percentage of Assets0.60.60.70.60.70.0
Percentage of Assets jnj:A1.65Notesdue20210.00.00.00.00.00.0

jnj:A2.05Notesdue2023


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value4994984984984970.0
Percentage of LongTermDebt112.199.699.60.00.00.0
Percentage of Assets0.30.30.30.30.40.0
Percentage of Assets jnj:A2.05Notesdue20230.00.00.00.00.00.0

jnj:A2.25Notesdue2022


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value9999989969950.0
Percentage of LongTermDebt224.5199.6199.20.00.0
Percentage of Assets0.60.60.70.60.0
Percentage of Assets jnj:A2.25Notesdue20220.00.00.00.00.0

jnj:A2.45Notesdue2021


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value350349349349348349
Percentage of LongTermDebt78.769.869.80.00.00.0
Percentage of Assets0.20.20.20.20.20.3
Percentage of Assets jnj:A2.45Notesdue20210.00.00.00.00.00.0

jnj:A2.45Notesdue2026


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value199419931992199019890.0
Percentage of LongTermDebt448.1398.6398.40.00.00.0
Percentage of Assets1.11.31.31.31.40.0
Percentage of Assets jnj:A2.45Notesdue20260.00.00.00.00.00.0

jnj:A2.625Notesdue2025


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value7487487487470.0
Percentage of LongTermDebt168.1149.6149.60.00.0
Percentage of Assets0.40.50.50.50.0
Percentage of Assets jnj:A2.625Notesdue20250.00.00.00.00.0

jnj:A2.900Notesdue2028


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value14951494149314920.0
Percentage of LongTermDebt336.0298.8298.60.00.0
Percentage of Assets0.90.91.00.90.0
Percentage of Assets jnj:A2.900Notesdue20280.00.00.00.00.0

jnj:A2.95Notesdue2027


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value9979969969950.0
Percentage of LongTermDebt224.0199.2199.20.00.0
Percentage of Assets0.60.60.70.60.0
Percentage of Assets jnj:A2.95Notesdue20270.00.00.00.00.0

jnj:A3.375Notesdue2023


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value803804805806807811
Percentage of LongTermDebt180.4160.8161.00.00.00.0
Percentage of Assets0.50.50.50.50.60.6
Percentage of Assets jnj:A3.375Notesdue20230.00.00.00.00.00.0

jnj:A3.400Notesdue2038


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value9919919909900.0
Percentage of LongTermDebt222.7198.2198.00.00.0
Percentage of Assets0.60.60.60.60.0
Percentage of Assets jnj:A3.400Notesdue20380.00.00.00.00.0

jnj:A3.500Notesdue2048


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value7427427427420.0
Percentage of LongTermDebt166.7148.4148.40.00.0
Percentage of Assets0.40.50.50.50.0
Percentage of Assets jnj:A3.500Notesdue20480.00.00.00.00.0

jnj:A3.55Notesdue2021


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value450449449448447448
Percentage of LongTermDebt101.189.889.80.00.00.0
Percentage of Assets0.30.30.30.30.30.3
Percentage of Assets jnj:A3.55Notesdue20210.00.00.00.00.00.0

jnj:A3.55Notesdue2036


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value9899899889879870.0
Percentage of LongTermDebt222.2197.8197.60.00.00.0
Percentage of Assets0.60.60.60.60.70.0
Percentage of Assets jnj:A3.55Notesdue20360.00.00.00.00.00.0

jnj:A3.625Notesdue2037


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value14881487148614860.0
Percentage of LongTermDebt334.4297.4297.20.00.0
Percentage of Assets0.90.91.00.90.0
Percentage of Assets jnj:A3.625Notesdue20370.00.00.00.00.0

jnj:A3.70Notesdue2046


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value197419731972197119700.0
Percentage of LongTermDebt443.6394.6394.40.00.00.0
Percentage of Assets1.11.31.31.31.40.0
Percentage of Assets jnj:A3.70Notesdue20460.00.00.00.00.00.0

jnj:A3.75Notesdue2047


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value9919919919900.0
Percentage of LongTermDebt222.7198.2198.20.00.0
Percentage of Assets0.60.60.60.60.0
Percentage of Assets jnj:A3.75Notesdue20470.00.00.00.00.0

jnj:A4.375Notesdue2033


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value855855856856857864
Percentage of LongTermDebt192.1171.0171.20.00.00.0
Percentage of Assets0.50.50.60.50.60.6
Percentage of Assets jnj:A4.375Notesdue20330.00.00.00.00.00.0

jnj:A4.50Debenturesdue2040


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value539539538538537540
Percentage of LongTermDebt121.1107.8107.60.00.00.0
Percentage of Assets0.30.30.40.30.40.4
Percentage of Assets jnj:A4.50Debenturesdue20400.00.00.00.00.00.0

jnj:A4.50Notesdue2043


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value496495495495495499
Percentage of LongTermDebt111.599.099.00.00.00.0
Percentage of Assets0.30.30.30.30.40.4
Percentage of Assets jnj:A4.50Notesdue20430.00.00.00.00.00.0

jnj:A4.85Notesdue2041


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value297297297296296298
Percentage of LongTermDebt66.759.459.40.00.00.0
Percentage of Assets0.20.20.20.20.20.2
Percentage of Assets jnj:A4.85Notesdue20410.00.00.00.00.00.0

jnj:A4.95Debenturesdue2033


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value498498498498497500
Percentage of LongTermDebt111.999.699.60.00.00.0
Percentage of Assets0.30.30.30.30.40.4
Percentage of Assets jnj:A4.95Debenturesdue20330.00.00.00.00.00.0

jnj:A5.50NotesDue2024


Long
Period End2021-01-032019-12-292018-12-30
Value679645627
Percentage of LongTermDebt152.6129.0125.4
Percentage of Assets0.40.40.4
Percentage of Assets jnj:A5.50NotesDue20240.00.00.0

jnj:A5.85Debenturesdue2038


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value696696696696695700
Percentage of LongTermDebt156.4139.2139.20.00.00.0
Percentage of Assets0.40.40.50.40.50.5
Percentage of Assets jnj:A5.85Debenturesdue20380.00.00.00.00.00.0

jnj:A5.95Notesdue2037


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value992992991991990996
Percentage of LongTermDebt222.9198.4198.20.00.00.0
Percentage of Assets0.60.60.60.60.70.7
Percentage of Assets jnj:A5.95Notesdue20370.00.00.00.00.00.0

jnj:A6.73Debenturesdue2023


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value250250250250249250
Percentage of LongTermDebt56.250.050.00.00.00.0
Percentage of Assets0.10.20.20.20.20.2
Percentage of Assets jnj:A6.73Debenturesdue20230.00.00.00.00.00.0

jnj:A6.95Notesdue2029


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value297297297296296297
Percentage of LongTermDebt66.759.459.40.00.00.0
Percentage of Assets0.20.20.20.20.20.2
Percentage of Assets jnj:A6.95Notesdue20290.00.00.00.00.00.0

us-gaap:OtherDebtSecurities


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-03
Value7.018247577104
Percentage of LongTermDebt1.63.64.80.00.00.0
Percentage of Assets0.00.00.00.00.10.1
Percentage of Assets us-gaap:OtherDebtSecurities0.00.00.00.00.00.0

us-gaap:LongTermDebt us-gaap:FairValueByMeasurementBasis

us-gaap:CarryingReportedAmountFairValueDisclosure


Long
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-30
Value344342759430320321742414614961151291509713001
Percentage of LongTermDebt7738.05518.86064.00.00.00.00.00.00.0
Percentage of Assets19.717.519.820.517.111.211.511.410.7
Percentage of Assets us-gaap:CarryingReportedAmountFairValueDisclosure0.00.00.00.00.00.00.00.00.0

us-gaap:LongTermDebt us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName, us-gaap:LineOfCreditFacility, us-gaap:LongtermDebtType

jnj:IdorsiaLTD, jnj:IdorsiaLTD, us-gaap:ConvertibleDebt


Long
Period End2020-09-27
Value445
Percentage of LongTermDebt0.0
Percentage of Assets0.3
Percentage of Assets jnj:IdorsiaLTD jnj:IdorsiaLTD us-gaap:ConvertibleDebt0.0

Long Term Debt Noncurrent

us-gaap:LongTermDebtNoncurrent

us-gaap:LongTermDebtNoncurrent


Long
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value30310302633263532680250622539326494269192769927660276842948029405298373067526675273632701522442235462453520233128571407314085149381512213152133031334313328974896431136311489114281152513010129691303113680925591568223
Percentage of LongTermDebtNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets17.217.518.719.115.816.416.817.317.918.418.118.918.919.019.517.117.918.615.916.817.514.99.610.610.711.611.510.09.810.010.07.77.89.39.59.610.011.211.411.712.28.68.98.7

Deferred Income Tax Liabilities Net

us-gaap:DeferredIncomeTaxLiabilitiesNet

us-gaap:DeferredIncomeTaxLiabilitiesNet


Deferred
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value90166507721456155532576659586526772573947506
Percentage of DeferredIncomeTaxLiabilitiesNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets5.13.84.13.33.53.73.84.25.04.94.9

Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent


Pension
Period End2021-01-032019-12-292018-12-302017-12-312017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value1077110663995110074960996158217835985918854951596339750997275517626770077849038899689789082790481808236835362156202612560876769
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets6.26.86.56.46.66.85.96.06.36.67.17.37.67.65.75.65.85.97.17.27.47.56.67.17.17.45.65.55.75.97.1

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanType

us-gaap:OtherPostretirementBenefitPlansDefinedBenefit


Pension
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value45204564401940734215
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent42.042.840.440.443.8
Percentage of Assets2.62.92.62.63.0
Percentage of Assets us-gaap:OtherPostretirementBenefitPlansDefinedBenefit0.00.00.00.00.0

us-gaap:PensionPlansDefinedBenefit


Pension
Period End2021-01-032019-12-292018-12-302017-12-312017-01-01
Value56365425522952514624
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent52.350.952.552.148.1
Percentage of Assets3.23.43.43.33.3
Percentage of Assets us-gaap:PensionPlansDefinedBenefit0.00.00.00.00.0

Other Liabilities Noncurrent

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OtherLiabilitiesNoncurrent


Other
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value1272411941119441214911034109441173411381101028928858985389281887690179102101179526953694141006297491024193038973860480347758737372717854889585698197855292079487105381063174737227700165675947
Percentage of OtherLiabilitiesNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets7.26.96.87.17.07.17.47.36.56.05.65.56.05.75.75.86.66.66.86.77.27.27.77.06.86.76.15.95.55.55.97.06.96.77.07.78.29.19.46.76.46.56.46.3

Operating Lease Liability

us-gaap:OperatingLeaseLiability

us-gaap:OperatingLeaseLiability


Operating
Period End2021-01-032019-12-292019-09-292019-06-30
Value11009859921011
Percentage of OperatingLeaseLiability100.0100.0100.0100.0
Percentage of Assets0.60.60.60.7

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest


Stockholders
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-282007-12-30
Value69580658346327864473629786129459471582106078558955597526462662889632556016073979719227034170418727697247372647711507155471131678786975276591780487658274053698046966566855648266376160434613665708061527621325986356579505884251143319
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets39.438.236.237.839.839.537.737.439.239.339.141.540.540.438.247.547.148.549.951.851.853.353.353.753.952.853.258.057.757.455.855.056.055.053.453.652.252.850.255.055.455.455.053.450.10.0

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents

us-gaap:AccumulatedDefinedBenefitPlansAdjustment


Stockholders
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-01-032014-12-282013-12-29
Value-6490.0-6724.0-6957.0-6304.0-6501.0-6696.0-6891.0-5716.0-5852.0-5989.0-6158.0-5593.0-5779.0-5964.0-6150.0-5623.0-5743.0-5861.0-5980.0-5298.0-6317.0-3009.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-9.3-10.2-11.0-9.8-10.3-10.9-11.6-9.8-9.6-10.2-10.3-8.7-9.2-9.4-10.2-7.6-8.0-8.3-8.5-7.4-9.1-4.1
Percentage of Assets-3.7-3.9-4.0-3.7-4.1-4.3-4.4-3.7-3.8-4.0-4.0-3.6-3.7-3.8-3.9-3.6-3.8-4.0-4.2-4.0-4.8-2.3
Percentage of Assets us-gaap:AccumulatedDefinedBenefitPlansAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedGainLossNetCashFlowHedgeParent


Stockholders
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302017-12-312017-01-01
Value18757652811636675-295.0-374.0-341.0-401.0-195.070-285.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest0.30.11.01.31.01.1-0.5-0.6-0.6-0.7-0.30.1-0.4
Percentage of Assets0.10.00.40.50.40.4-0.2-0.2-0.2-0.3-0.10.0-0.2
Percentage of Assets us-gaap:AccumulatedGainLossNetCashFlowHedgeParent0.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss


Stockholders
Period End2021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-01-032014-12-282013-12-29
Value1.01.01.00.02.00.01.01.00.00.0-1.00.00.0232269354321411604257106
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest0.00.00.00.00.00.00.00.00.00.0-0.00.00.00.40.40.50.50.60.80.40.1
Percentage of Assets0.00.00.00.00.00.00.00.00.00.0-0.00.00.00.10.20.20.20.30.50.20.1
Percentage of Assets us-gaap:AccumulatedNetUnrealizedInvestmentGainLoss0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedOtherComprehensiveIncome


Stockholders
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-28
Value-15100.0-15328.0-15242.0-14938.0-15533.0-16243.0-15891.0-15533.0-14969.0-15517.0-15222.0-14647.0-14777.0-12608.0-13199.0-12747.0-13234.0-14522.0-14901.0-13165.0-10722.0-2860.0-5810.0-5632.0-3531.0-3058.0-4955.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-21.7-23.3-24.1-23.2-24.7-26.5-26.7-26.7-24.6-26.3-25.5-22.7-23.5-19.9-21.9-17.2-18.4-20.6-21.2-18.5-15.4-3.9-9.0-9.9-6.2-6.0-11.7
Percentage of Assets-8.6-8.9-8.7-8.8-9.8-10.5-10.1-10.0-9.7-10.3-10.0-9.4-9.5-8.0-8.4-8.2-8.7-10.0-10.6-9.9-8.2-2.2-4.8-5.0-3.4-3.2-5.8
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedTranslationAdjustment


Stockholders
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-01-032014-12-282013-12-29
Value-8797.0-8662.0-8938.0-9446.0-9668.0-10224.0-8705.0-9444.0-8777.0-9127.0-8869.0-9069.0-8918.0-6728.0-7351.0-7450.0-7809.0-8652.0-9047.0-8435.0-4803.0-202.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-12.6-13.2-14.1-14.7-15.4-16.7-14.6-16.2-14.4-15.5-14.8-14.0-14.2-10.6-12.2-10.1-10.9-12.3-12.8-11.9-6.9-0.3
Percentage of Assets-5.0-5.0-5.1-5.5-6.1-6.6-5.5-6.1-5.7-6.1-5.8-5.8-5.7-4.3-4.7-4.8-5.1-6.0-6.4-6.3-3.7-0.2
Percentage of Assets us-gaap:AccumulatedTranslationAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Stockholders
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-282007-12-30
Value1201541165081138901148311138981129011106591092421098091066501062161076171061231043391017931105511038799724589493859928125177773703066337955280
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest172.7177.0180.0178.1180.9184.2186.1187.7180.7180.9177.8166.5168.7164.9169.2157.0146.0139.4120.8132.7142.3137.5139.0149.1127.6
Percentage of Assets68.167.565.167.371.972.870.270.270.871.169.469.168.366.664.778.377.974.267.470.971.575.674.374.60.0
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:TreasuryStock


Stockholders
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-282007-12-30
Value-38594.0-38466.0-38490.0-38540.0-38507.0-38484.0-38417.0-38619.0-37175.0-35298.0-34362.0-31464.0-31577.0-31596.0-31554.0-28352.0-22684.0-19891.0-15700.0-18476.0-21659.0-20783.0-19780.0-19033.0-14388.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-55.5-58.4-60.8-59.8-61.1-62.8-64.6-66.3-61.2-59.9-57.5-48.7-50.2-50.0-52.5-40.3-31.9-28.5-21.2-28.5-37.9-36.7-39.1-44.8-33.2
Percentage of Assets-21.9-22.3-22.0-22.6-24.3-24.8-24.4-24.8-24.0-23.5-22.5-20.2-20.3-20.2-20.1-20.1-17.0-15.2-11.8-15.2-19.1-20.2-20.9-22.40.0
Percentage of Assets us-gaap:TreasuryStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Retained Earnings Accumulated Deficit

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:RetainedEarningsAccumulatedDeficit


Retained
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-03
Value12015411650811389011483111389811290111065910924210980910665010621610761710612310433910179311480511320811164311055110886010673810499010387910274810135298656972459656093745913878949387703894498724285992848808353083103812518263480836795157777370306
Percentage of RetainedEarningsAccumulatedDeficit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets68.167.565.167.371.972.870.270.270.871.169.469.168.366.664.773.874.177.078.377.676.377.177.977.176.876.774.273.169.368.567.469.171.971.870.971.472.271.571.573.972.173.575.674.3

Accumulated Other Comprehensive Income Loss Net Of Tax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax


Accumulated
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-28
Value-15100.0-15328.0-15242.0-14938.0-15533.0-16243.0-15891.0-15533.0-14969.0-15517.0-15222.0-14647.0-14777.0-12608.0-13199.0-12747.0-13234.0-14522.0-14901.0-12715.0-12707.0-12391.0-13165.0-12861.0-12054.0-13300.0-10722.0-5382.0-3007.0-2645.0-2860.0-5346.0-6810.0-6689.0-5810.0-4925.0-6204.0-4540.0-5632.0-3068.0-1192.0-2020.0-3531.0-3058.0-4955.0
Percentage of AccumulatedOtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-8.6-8.9-8.7-8.8-9.8-10.5-10.1-10.0-9.7-10.3-10.0-9.4-9.5-8.0-8.4-8.2-8.7-10.0-10.6-9.1-9.1-9.1-9.9-9.7-9.1-10.3-8.2-4.1-2.2-2.0-2.2-4.2-5.5-5.5-4.8-4.1-5.4-3.9-5.0-2.7-1.1-1.9-3.4-3.2-5.8

Treasury Stock Value

us-gaap:TreasuryStockValue

us-gaap:TreasuryStockValue


Treasury
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-01-032008-12-282007-12-30
Value38594384663849038540385073848438417386193717535298343623146431577315963155431199311722990028352264962467823072226842145321287205981989117707158101528015700156731609416818184761931420012203172165921159206322075220783197801903314388
Percentage of TreasuryStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets21.922.322.022.624.324.824.424.824.023.522.520.220.320.220.120.020.420.620.118.917.716.917.016.116.116.015.213.411.711.511.812.312.913.815.216.217.317.519.118.918.419.220.220.922.40.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value53144074838334523358639875275948354362446272607936066105626657722913665353614990176361255200287243654654552939234139594750512277337644974728279534514622390923163824503438373690
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax22.818.339.818.816.230.836.328.917.730.630.829.218.030.231.930.616.436.730.127.010.135.829.216.523.925.228.421.722.533.828.313.019.226.428.717.321.228.923.614.324.433.625.023.6

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value-419.0-185.0-4819.0-7522.0-581.0-1344.0-1645.0-1788.0-1417.02228-4269.0-201.0-925.0-505.0-1180.0-12247.0-936.0-2174.0-2372.01322-1537.0-1001.0-3554.0-1789.0-2922.0735-8092.0-2026.0-1578.0-1553.0-569.0-1403.0-2503.011398-17461.040566238-1590.0-10700.01440-1404.0-1875.0-2693.0-1882.0
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-1.8-0.8-22.9-41.0-2.8-6.5-7.9-8.7-7.110.9-21.0-1.0-4.6-2.5-6.0-65.0-5.3-12.0-13.37.2-8.8-5.9-20.0-10.3-16.04.0-41.5-11.2-8.6-8.8-3.2-8.0-14.366.8-106.025.138.4-9.9-64.58.9-9.0-12.5-17.6-12.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value-3279.0-5125.04196-357.0-4315.0-4072.0-3893.0-4534.0-5516.0-6389.0-3477.0-2674.0-5970.0-3537.0-2069.0-1917.0-150.0-3464.0-3445.0-1464.0-178.0-1825.0-2503.0-3227.0-619.0-5716.0-2868.0-3057.01182-4519.0-1977.0-777.0-1471.0-14505.0-3403.0-1183.0-756.0-2232.0-639.0-825.02606-1699.0-2065.0-3822.0
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-14.1-23.019.9-1.9-20.9-19.6-18.8-22.1-27.6-31.3-17.1-12.8-29.8-17.5-10.5-10.2-0.8-19.1-19.3-7.9-1.0-10.7-14.1-18.6-3.4-31.0-14.7-16.96.4-25.7-11.1-4.4-8.4-85.1-20.7-7.3-4.7-13.9-3.9-5.116.7-11.3-13.5-24.5

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect


Cash
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-30
Value1661-1314.07791-4356.0-1775.010561873-358.0-3373.02051
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.1-5.937.0-23.8-8.65.19.0-1.7-16.810.1

Deferred Income Tax Expense Benefit

us-gaap:DeferredIncomeTaxExpenseBenefit

us-gaap:DeferredIncomeTaxExpenseBenefit


Deferred
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value45-730.0190-482.054-350.0-1432.0-332.0-362.01900338-329.0442813-335.0-45.0-27.0-556.0100-278.0393-51.0-261.0545144-296.098495-383.0-316.0-273.0365285187-1068.055713-345.0-500.0-4.0-288.040-356.0960
Percentage of DeferredIncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Depreciation Depletion And Amortization

us-gaap:DepreciationDepletionAndAmortization

us-gaap:DepreciationDepletionAndAmortization


Depreciation
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value1839189418181726174718161727170517611735173117171746186917111150912105590890089192988989599193995210131102976990103610361005852773843783777755769725711734
Percentage of DepreciationDepletionAndAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Increase Decrease In Accounts Receivable

us-gaap:IncreaseDecreaseInAccountsReceivable

us-gaap:IncreaseDecreaseInAccountsReceivable


Increase
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value-38.01604-80.0-292.0812-376.0329493-157.014551510479333-176.038096329-362.0709389-276.0421765-152.0-185.0158426-339.032421343410361-370.0215426-87.0-33.0609-378.03026529
Percentage of IncreaseDecreaseInAccountsReceivable100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Increase Decrease In Inventories

us-gaap:IncreaseDecreaseInInventories

us-gaap:IncreaseDecreaseInInventories


Increase
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value123695147478159-147.01.054369-133.0286169322-774.0-228.053368-159.0-35.02531901822612762249393512-177.0252259288-592.0-25.0169449-72.0167168452-1.0109-105.0193
Percentage of IncreaseDecreaseInInventories100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value53144074838334523358639875275948354362446272607936066105626657722913665353614990176361255200287243654654552939234139594750512277337644974728279534514622390923163824503438373690
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax22.818.339.818.816.230.836.328.917.730.630.829.218.030.231.930.616.436.730.127.010.135.829.216.523.925.228.421.722.533.828.313.019.226.428.717.321.228.923.614.324.433.625.023.6

Net Income Loss

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032016-01-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-042010-01-032009-09-272009-06-282009-03-29
Value6278619735543626579640101753560737493042393439544367-10713.03764382744223814427239974292321533584516432025214749432647273519298238333497256729681408391021832022776347619423417344945262206334532083507
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax26.927.816.919.828.019.38.527.318.714.919.319.021.8-53.019.220.324.921.124.021.624.618.119.625.424.913.825.722.226.119.217.021.420.014.617.48.524.21.320.016.721.512.422.822.529.013.322.221.123.3

us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value6278619735543626579640101753560737493042393439544367
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax26.927.816.919.828.019.38.527.318.714.919.319.021.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.0

Share Based Compensation

us-gaap:ShareBasedCompensation

us-gaap:ShareBasedCompensation


Share
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value354307256326263160245314258156242312268204236293229174225274205203270204146206242198144161229194147146196173137145187152140169148157
Percentage of ShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value-419.0-185.0-4819.0-7522.0-581.0-1344.0-1645.0-1788.0-1417.02228-4269.0-201.0-925.0-505.0-1180.0-12247.0-936.0-2174.0-2372.01322-1537.0-1001.0-3554.0-1789.0-2922.0735-8092.0-2026.0-1578.0-1553.0-569.0-1403.0-2503.011398-17461.040566238-1590.0-10700.01440-1404.0-1875.0-2693.0-1882.0
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-1.8-0.8-22.9-41.0-2.8-6.5-7.9-8.7-7.110.9-21.0-1.0-4.6-2.5-6.0-65.0-5.3-12.0-13.37.2-8.8-5.9-20.0-10.3-16.04.0-41.5-11.2-8.6-8.8-3.2-8.0-14.366.8-106.025.138.4-9.9-64.58.9-9.0-12.5-17.6-12.0

Payments To Acquire Property Plant And Equipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment


Payments
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value81367773766262512607458376561318819875658124079068956010937377576397897655431496751837630142980977158611526825985021128711618436959528500397
Percentage of PaymentsToAcquirePropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Payments To Acquire Investments

us-gaap:PaymentsToAcquireInvestments

us-gaap:PaymentsToAcquireInvestments


Payments
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value627059947692648720641236116778773014713204403548355571677455062731016674491006279531365171629129843211925542753405014501835514597362628132398443886241578410365109398434493246
Percentage of PaymentsToAcquireInvestments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value-3279.0-5125.04196-357.0-4315.0-4072.0-3893.0-4534.0-5516.0-6389.0-3477.0-2674.0-5970.0-3537.0-2069.0-1917.0-150.0-3464.0-3445.0-1464.0-178.0-1825.0-2503.0-3227.0-619.0-5716.0-2868.0-3057.01182-4519.0-1977.0-777.0-1471.0-14505.0-3403.0-1183.0-756.0-2232.0-639.0-825.02606-1699.0-2065.0-3822.0
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-14.1-23.019.9-1.9-20.9-19.6-18.8-22.1-27.6-31.3-17.1-12.8-29.8-17.5-10.5-10.2-0.8-19.1-19.3-7.9-1.0-10.7-14.1-18.6-3.4-31.0-14.7-16.96.4-25.7-11.1-4.4-8.4-85.1-20.7-7.3-4.7-13.9-3.9-5.116.7-11.3-13.5-24.5

Proceeds From Issuance Of Long Term Debt

us-gaap:ProceedsFromIssuanceOfLongTermDebt

us-gaap:ProceedsFromIssuanceOfLongTermDebt


Proceeds
Period End2021-07-042021-04-042020-09-272019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-02
Value0.01.074302.00.01.00.0-1.03.01.02.045271.00.04464530.0451674350.00.03.020004.0-3.0163500450.06.02910.04.02.0-1.06743968.039
Percentage of ProceedsFromIssuanceOfLongTermDebt0.0100.0100.0100.00.0100.00.0100.0100.0100.0100.0100.0100.00.0100.0100.00.0100.0100.00.00.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Repayments Of Long Term Debt

us-gaap:RepaymentsOfLongTermDebt

us-gaap:RepaymentsOfLongTermDebt


Repayments
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value45010015510.01118153.03.010026459011.08.07531009132.0127017922146.05.0165710.0175621622715031.08.0786-20.0304.07.02.03.0119.04.08.0
Percentage of RepaymentsOfLongTermDebt100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Payments For Repurchase Of Common Stock

us-gaap:PaymentsForRepurchaseOfCommonStock

us-gaap:PaymentsForRepurchaseOfCommonStock


Payments
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value6311438483706171142616282486220638084711451444815311189033422025220323622389300896219827432415119277448830500.00.00.00.012852678537434944351285732397383
Percentage of PaymentsForRepurchaseOfCommonStock100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Effective Income Tax Rate Continuing Operations

us-gaap:EffectiveIncomeTaxRateContinuingOperations

us-gaap:EffectiveIncomeTaxRateContinuingOperations


Effective
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-032011-01-022010-10-032010-07-042010-04-04
Value-5.116.612.502-0.0120.11-0.026-0.0310.0320.152-0.026-0.0280.0010.2030.7210.004-0.0060.207-0.0130.007-0.0180.189-0.009-0.0060.225-0.0210.0460.0520.129-0.083-0.0010.0110.179-0.0190.0070.0240.2250.0030.003-0.0170.229-0.013-0.014-0.0390.279
Percentage of EffectiveIncomeTaxRateContinuingOperations100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber


Share
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-282007-12-30
Value1141111091111131161151191340.179459193212215228
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice


Share
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-282007-12-30
Value116.22105.6398.2990.4883.1676.4170.3764.761.5860.159.6858.6658.1456.83
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Deferred Tax Liabilities

us-gaap:DeferredTaxLiabilities

us-gaap:DeferredTaxLiabilities


Deferred
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-03
Value11819100871127111166690671597540738375654284-3600.0-3148.0
Percentage of DeferredTaxLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Deferred Tax Assets Net

us-gaap:DeferredTaxAssetsNet

us-gaap:DeferredTaxAssetsNet


Deferred
Period End2021-01-032019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-03
Value131381194811405990210144100871129510840120981158694669983
Percentage of DeferredTaxAssetsNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Unrecognized Tax Benefits

us-gaap:UnrecognizedTaxBenefits

us-gaap:UnrecognizedTaxBenefits


Unrecognized
Period End2021-07-042021-04-042021-01-032020-09-272020-06-282020-03-292019-12-292018-12-302017-12-312017-01-012016-01-032014-12-282013-12-292012-12-302012-01-012011-01-022010-01-032008-12-282007-12-30
Value3300330033733300310032003853332631513041308024652729305426992307240319781653
Percentage of UnrecognizedTaxBenefits100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:UnrecognizedTaxBenefits us-gaap:BalanceSheetLocation

jnj:AccruedTaxesOnIncome


Unrecognized
Period End2020-09-272020-06-282020-03-292019-12-29
Value100200200900
Percentage of UnrecognizedTaxBenefits3.06.56.223.4

jnj:AmountPrepaidAndDueToManufacturers

jnj:AmountPrepaidAndDueToManufacturers


Amount
Period End2021-04-042020-09-27
Value1000800
Percentage of AmountPrepaidAndDueToManufacturers100.0100.0

jnj:CostOfGoodsSoldPercentToSales

jnj:CostOfGoodsSoldPercentToSales


Cost
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value32.531.733.10.3590.3410.3310.3380.330.3240.3330.3310.3510.3090.3030.3080.2890.3050.3050.3010.3040.2920.310.3010.3040.3070.3170.3280.3120.3040.3170.3120.295
Percentage of CostOfGoodsSoldPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent

jnj:EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent


Effective
Period End2020-09-27
Value1.1
Percentage of EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent100.0

jnj:EffectiveIncomeTaxReconciliationPercentRevisedAgreementFromLitigationSettlement

jnj:EffectiveIncomeTaxReconciliationPercentRevisedAgreementFromLitigationSettlement


Effective
Period End2020-09-272019-09-29
Value21.423.0
Percentage of EffectiveIncomeTaxReconciliationPercentRevisedAgreementFromLitigationSettlement100.0100.0

jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent

jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent


Effective
Period End2021-01-032019-12-29
Value-2.20.017
Percentage of EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent100.0100.0

jnj:EquityFairValueAdjustmentImpairmentLoss us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

jnj:EquityFairValueAdjustmentImpairmentLoss

us-gaap:EquitySecurities, jnj:EquityInvestmentswithoutReadilyDeterminableValue


Equity
Period End2021-07-042021-04-04
Value40000000.0-55000000.0
Percentage of EquityFairValueAdjustmentImpairmentLoss100.0100.0

jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod us-gaap:FairValueByAssetClass, us-gaap:OtherInvestmentNotReadilyMarketable

jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod

us-gaap:EquitySecurities, jnj:EquityInvestmentswithReadilyDeterminableValue


Equity
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value197.0-313.01395.0-47.0-9.0-16.01762610.0-36.07.0
Percentage of EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EquitySecurities, jnj:EquityInvestmentswithoutReadilyDeterminableValue


Equity
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value-17.08138131523276.01336211883
Percentage of EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod-89.51157.1-12.19.4300.0-48.9-300.0-37.57.4138.5210.0-50.01185.7

jnj:EquityMethodInvestmentRetainedAfterDisposalOwnershipInterestAfterDisposalShares us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeName

jnj:EquityMethodInvestmentRetainedAfterDisposalOwnershipInterestAfterDisposalShares

jnj:IdorsiaLTD


Equity
Period End2020-09-27
Value38
Percentage of EquityMethodInvestmentRetainedAfterDisposalOwnershipInterestAfterDisposalShares100.0

jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue

jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue


Fair
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-31
Value-7.015-150.039-977.034823.032
Percentage of FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset

jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset


Federal
Period End2020-09-272020-06-282020-03-29
Value0.0100300
Percentage of FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset0.0100.0100.0

jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent

jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent


Federal
Period End2020-09-272020-06-282020-03-29
Value-1.12.51.3
Percentage of FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent100.0100.0100.0

jnj:GrossProfitPercentToSales

jnj:GrossProfitPercentToSales


Gross
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value67.568.366.90.6410.6590.6690.6620.670.6760.6670.6690.6490.6910.6970.6920.7110.6950.6950.6990.6960.7080.690.6990.6960.6930.6830.6720.6880.6960.6830.6880.705
Percentage of GrossProfitPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales

jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales


Income
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value28.633.320.90.2150.3150.0790.3420.2210.2170.2390.2740.2440.2520.3140.2960.2650.3030.2410.3230.3210.3690.2890.2990.2090.2680.2430.2110.1240.3130.2570.2060.279
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IncomeTaxExpenseBenefitPercentToSales

jnj:IncomeTaxExpenseBenefitPercentToSales


Income
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value1.75.54.00.0170.035-0.0060.0690.0340.0240.0490.0560.0520.0490.0650.0560.0490.0570.0450.0690.0720.1120.0670.0380.0390.0540.0430.0570.0390.0710.0570.0390.064
Percentage of IncomeTaxExpenseBenefitPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI

jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI


Increase
Period End2021-07-042020-03-29
Value1700200
Percentage of IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI100.0100.0

jnj:InterestExpensePercentToSales

jnj:InterestExpensePercentToSales


Interest
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value0.20.30.20.0030.0010.0020.0040.0050.0120.0120.0130.0120.0120.0120.010.0110.0090.0070.0070.0080.0070.0070.0080.0060.0070.0070.0080.0090.0090.0080.0080.007
Percentage of InterestExpensePercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:InvestmentIncomeInterestPercentToSales

jnj:InvestmentIncomeInterestPercentToSales


Investment
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value-0.1-0.1-0.1-0.001-0.003-0.004-0.004-0.005-0.009-0.006-0.006-0.004-0.006-0.007-0.005-0.005-0.005-0.002-0.001-0.001-0.001-0.001-0.001-0.001-0.001-0.0010.0010.0010.0010.0010.0010.001
Percentage of InvestmentIncomeInterestPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue us-gaap:ProductOrService, us-gaap:LitigationStatus

jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue

jnj:Opioid, us-gaap:SettledLitigation


Loss
Period End2021-06-30
Value263
Percentage of LossContingencyDamagesAwardedAdditionalReimbursementValue100.0

jnj:NetIncomeAttributableToParentPercentToSales

jnj:NetIncomeAttributableToParentPercentToSales


Net
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-02
Value26.927.816.90.1980.280.0850.2730.1870.1930.190.2180.1920.2030.2490.240.2160.2460.1960.2540.2490.2570.2220.2610.170.2140.20.1740.0850.2420.2
Percentage of NetIncomeAttributableToParentPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax

jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value41416.05.06.00.06.05.07.0276.05.06.0
Percentage of OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax

jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-01
Value-275.0-274.0-203.0-200.0-201.01174-142.0-142.0-176.0630-192.0-190.0-192.0
Percentage of OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:OtherNonOperatingIncomeExpensePercentToSales

jnj:OtherNonOperatingIncomeExpensePercentToSales


Other
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value-2.1-3.95.70.001-0.0330.203-0.082-0.00100.0170.003-0.0120.031-0.009-0.0020.03-0.0020.025-0.053-0.02-0.0730.0110.0050.0540.0090.030.005-0.1220.0380.019-0.0130.001
Percentage of OtherNonOperatingIncomeExpensePercentToSales100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PercentageChangeInOperatingIncomeLoss

jnj:PercentageChangeInOperatingIncomeLoss


Percentage
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-03
Value69.114.113.388-0.440.472-0.6280.416-0.193-0.0770.047-0.017-0.093-0.0320.0530.281-0.146-0.05-0.3950.020.0280.8570.1740.2730.021.355-0.155-0.177-0.2490.0850.066-0.192
Percentage of PercentageChangeInOperatingIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PercentageChangeInOperatingIncomeLoss us-gaap:ConsolidationItems

us-gaap:OperatingSegments


Percentage
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-28
Value64.715.313.286-0.4240.451-0.6080.378-0.211-0.0910.042-0.005-0.072-0.0260.0610.259-0.137-0.059-0.3790.025
Percentage of PercentageChangeInOperatingIncomeLoss93.6108.599.296.495.696.890.9109.3118.289.429.477.481.2115.192.293.8118.095.9125.0

jnj:PercentageChangeInOperatingIncomeLoss us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, jnj:Consumer


Percentage
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-28
Value96.22.3-70.8-0.9210.0390.28-0.510.352-0.4190.26-0.0810.2930.1520.053-0.1630.801-0.1210.993-0.549
Percentage of PercentageChangeInOperatingIncomeLoss139.216.3-528.8209.38.3-44.6-122.6-182.4544.2553.2476.5-315.1-475.0100.0-58.0-548.6242.0-251.4-2745.0

us-gaap:OperatingSegments, jnj:MedicalDevices


Percentage
Period End2021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-28
Value-19.6-27.4-0.9960.3530.0991.025-0.052-0.084-0.1980.01-0.0940.056-0.0080.828-0.407-0.29-0.754-0.07
Percentage of PercentageChangeInOperatingIncomeLoss-139.0-204.7226.474.8-15.8246.426.9109.1-421.3-58.8101.1-175.0-15.1294.7278.8580.0190.9-350.0

us-gaap:OperatingSegments, jnj:Pharmaceutical


Percentage
Period End2021-07-042021-04-042020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-28
Value-3.536.20.2280.645-0.2530.007-0.3640.0070.0690.001-0.137-0.0740.0950.211-0.1060.129-0.1590.188
Percentage of PercentageChangeInOperatingIncomeLoss-5.1256.7-51.8136.740.31.7188.6-9.1146.8-5.9147.3231.2179.275.172.6-258.040.3940.0

jnj:PercentageChangeInSalesByGeographicArea

jnj:PercentageChangeInSalesByGeographicArea


Percentage
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value27.17.91.7-0.1080.0330.019-0.0130.0010.0360.1060.1260.1030.0190.0160.0420.0390.006-0.074-0.088-0.0410.0510.0910.0350.0310.0850.0850.065-0.007-0.0020.0680.0830.035
Percentage of PercentageChangeInSalesByGeographicArea100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:PercentageChangeInSalesByGeographicArea us-gaap:StatementGeographical

country:US


Percentage
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-02
Value24.93.92.7-0.0830.0560.012-0.0220.0180.0360.0940.0610.0970.0160.0060.0670.0740.072-0.006-0.0240.0590.1160.1490.0220.0170.080.1120.134-0.012-0.051-0.037
Percentage of PercentageChangeInSalesByGeographicArea91.949.4158.876.9169.763.2169.21800.0100.088.748.494.284.237.5159.5189.71200.08.127.3-143.9227.5163.762.954.894.1131.8206.2171.42550.0-54.4

jnj:AsiaPacificAfrica


Percentage
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-30
Value21.019.4-2.7-0.093-0.0310.0730.0340.0230.0670.1350.2010.0850.0320.0310.0540.017-0.007-0.093-0.064-0.0980.0090.0270.036-0.0360.041
Percentage of PercentageChangeInSalesByGeographicArea77.5245.6-158.886.1-93.9384.2-261.52300.0186.1127.4159.582.5168.4193.8128.643.6-116.7125.772.7239.017.629.7102.9-116.148.2

jnj:WesternHemisphereExcludingUS


Percentage
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-30
Value20.6-5.1-12.9-0.221-0.001-0.04-0.055-0.041-0.0120.0270.0780.124-0.0280.092-0.0460.027-0.188-0.196-0.194-0.033-0.012-0.022-0.0490.010.102
Percentage of PercentageChangeInSalesByGeographicArea76.0-64.6-758.8204.6-3.0-210.5423.1-4100.0-33.325.561.9120.4-147.4575.0-109.569.2-3133.3264.9220.580.5-23.5-24.2-140.032.3120.0

srt:Europe


Percentage
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-31
Value39.512.18.0-0.1420.0470.01-0.016-0.039
Percentage of PercentageChangeInSalesByGeographicArea145.8153.2470.6131.5142.452.6123.1-3900.0

jnj:PercentageChangeInSalesBySegmentOfBusiness

jnj:PercentageChangeInSalesBySegmentOfBusiness


Percentage
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-03
Value27.17.91.7-0.1080.0330.0040.019-0.0130.001-0.0210.0360.1060.1260.0170.1030.0190.0160.0420.0390.006-0.074-0.088-0.0410.0510.0910.0350.0310.0850.0850.065-0.007-0.0020.0680.083
Percentage of PercentageChangeInSalesBySegmentOfBusiness100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits

jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits


Proceeds
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-12-292019-09-292019-06-302019-03-312018-12-302018-09-302018-07-012018-04-012017-12-312017-10-012017-07-022017-04-022017-01-012016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-12-282014-09-282014-06-292014-03-302013-12-292013-09-292013-06-302013-03-312012-12-302012-09-302012-07-012012-04-012012-01-012011-10-022011-07-032011-04-03
Value30723621437633237411736994469318966620813531740277183-7.0936591945843763584625863784297191123903669268880300229532185
Percentage of ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities

jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities


Proceeds
Period End2021-07-042021-04-04
Value-82.0212
Percentage of ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities100.0100.0

jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities

jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities


Proceeds
Period End2021-07-042021-04-042020-06-282020-03-29
Value-310.0751-1071.01743
Percentage of ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities100.0100.0100.0100.0

jnj:Proceedsfromcreditsupportagreements

jnj:Proceedsfromcreditsupportagreements


Proceedsfromcreditsupportagreements
Period End2020-09-272020-06-282020-03-292019-06-302019-03-31
Value-547.0-1071.017430.00.0
Percentage of Proceedsfromcreditsupportagreements100.0100.0100.00.00.0

jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales

jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales


Research
Period End2021-07-042021-04-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022017-04-022016-10-022016-07-032016-04-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013-09-292013-06-302013-03-312012-09-302012-07-012012-04-012011-10-022011-07-032011-04-03
Value14.614.213.50.1480.1250.1250.130.1430.1230.1270.120.1310.1210.1160.1220.1220.1150.1260.120.1090.110.1030.1010.1160.1090.1020.1130.1070.1020.1110.1130.108
Percentage of ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

jnj:ResearchAndDevelopmentInProcessPercentToSales

jnj:ResearchAndDevelopmentInProcessPercentToSales


Research
Period End2021-07-042020-09-272020-06-282020-03-292019-09-292019-06-302019-03-312018-09-302018-07-012018-04-012017-10-012017-07-022016-10-022016-07-032015-09-272015-06-282015-03-292014-09-282014-06-292014-03-302013